Title: A non-randomized, open-label, dose-finding, first-in-human, trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection.

Authors: Yoshie Umemura, M.D.[1], Daniel Orringer, M.D.[2], Larry Junck, M.D.[1], Maria L. Varela, Ph.D.[2,3,5], Molly E.J. West, M.S.[2,3,5], Syed M. Faisal, Ph.D.[2,3,5], Andrea Comba, Ph.D.[2,3,5], Jason Heth, M.D.[2], Oren Sagher, M.D.[2], Denise Leung, M.D.[1], Aaron Mammoser, M.D.[1], Shawn Hervey-Jumper, M.D.[2], Daniel Zamler, B.S.[2], Viveka N. Yadav, Ph.D.[2], Patrick Dunn, B.S.[2], Wajd Al-Holou, M.D.[2], Todd Hollon, M.D.[2], Michelle M. Kim, M.D.[6], Daniel R. Wahl, M.D., Ph.D.[6], Sandra Camelo-Piragua, M.D[7], Andrew P. Lieberman, M.D., Ph.D.[7], Sriram Venneti, M.D., Ph.D.[7], Paul McKeever, M.D., Ph.D.[7], Theodore Lawrence, M.D., Ph.D.[6], Ryo Kurokawa, M.D., Ph.D.[8], Karen Sagher[2], B.S.[2] David Altshuler, M.D.[2], Lili Zhao, Ph.D.[9], Karin Muraszko, M.D.[2], Maria G. Castro, Ph.D.[2,3,5], Pedro R. Lowenstein, M.D., Ph.D.[2,3,4,5].

Affiliations: [1]Depts. Of Neurology, [2]Neurosurgery, [3]Cell and Developmental Biology, [4]Department of Biomedical Engineering, [5]The Rogel Cancer Center, [6]Radiation Oncology, [7]Pathology, and [8]Radiology, The University of Michigan School of Medicine, and [9]Dept. of Biostatistics, The University of Michigan School of Public Health.

Acknowledgements: Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai Medical Center, and The Rogel Cancer Center at The University of Michigan. [clinicaltrials.gov: NCT01811992].

Corresponding Author:
Pedro R. Lowenstein, M.D., Ph.D.
Address: 4570 MSRB II, Ann Arbor, MI 48109-0650
Email: pedrol@umich.edu
Phone: 734-764-0851

Running Head: Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma.

Abstract

Background: High-grade gliomas are fatal with universally poor prognosis. Initiation of effective cancer immune responses requires functional immune cells, particularly afferent antigen-presenting cells, which are typically absent from the brain parenchyma. To overcome this limitation, two adenoviral vectors expressing HSV1-TK and Flt3L were combined to target human gliomas. This first-in-human trial assessed safety, cytotoxicity, and recruitment of immune cells to the brain, in support of a future phase 1b/2 clinical trial.

Methods: Treatment-naïve high-grade glioma adult patients received injections of adenoviral vectors expressing HSV1-TK and Flt3L to the tumor bed, following maximal safe resection, at six escalating doses ranging from a total of $1.1x10^{10}$ to a maximum of $2x10^{11}$ viral particles. This was followed by two 14-day courses of valacyclovir and standard upfront chemoradiation. Key inclusion criteria were age between 18 to 75, KPS≥70, and treatment-naïve possible high-grade glioma amenable to gross total resection. Patients have consented pre-operatively, and definitive enrollment occurred intraoperatively upon pathology confirmation of malignant glioma.

Findings: The treatment was well-tolerated without dose-limiting toxicity in patients with glioblastoma (n=17) (including 3 of the gliosarcoma variant), or anaplastic ependymoma (n=1). The maximal-tolerated dose was not reached. The median overall survival was 21.3 months (95%CI: 11.1, 26.1), with seven patients surviving for >2 years, three patients surviving for >3 years, and one patient still alive 57 months after enrollment. Tissue from subsequent re-resections from eight subjects showed elevated markers for $CD3^+$, $CD8^+$ T cells, and pDCs, suggesting the potential stimulation of anti-glioma immunity. Additionally, we detected biological activities from both viral vectors: (i) an increase in serum levels of Flt3L two weeks after vector administration, and (ii) expression of HSV1-TK in neurons, astrocytes, and SOX2+ cells in brain tumor samples up to 17 months post-vector injection into the brain.

Interpretation: Use of two adenoviral vectors expressing HSV1-TK and Flt3L appears to be both safe and feasible. Promising evidence from multiplex immunocytochemical analyses shows the presence of the expected immune infiltration, i.e., pDCs, along with persistent vector expression lasting up to 17 months post-injection. Moreover, the two-year survival rate of 38.8% is promising, suggesting that this approach warrants further investigation in a phase 1b/2 clinical trial.

Funding: Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai Medical Center, and The Rogel Cancer Center at The University of Michigan; clinicaltrials.gov: NCT01811992.

Introduction

High-grade gliomas (HGG), of astrocytic, oligodendroglial or ependymal variants, are the most common types of primary brain tumor in adults.[1] HGGs are associated with poor prognosis, in spite of standard therapy, leading to a median overall survival (OS) around 14-16 months despite aggressive treatment with surgical resection and chemoradiation.[2] Gene therapy for malignant gliomas using viral vectors encoding a direct or conditional tumoricidal approach has been shown to be safe in humans, though it has not demonstrated clinically significant benefits to date in large scale clinical trials.[3,4] Important challenges of gene therapy remain the low efficacy of direct tumor cell killing *in situ* and limited tumor and brain distribution of the transgenic therapeutic products preventing elimination of infiltrating malignant cells located at various distances from the primary tumor site.[5-10]

Initiation of an effective immune response against cancer requires functional dendritic cells, which are absent from the non-inflamed central nervous system (CNS),[11] possibly underlying the lack of anti-HGG immune responses (Figure 1A). Treatment with Flt3L at the tumor bed, a cytokine known to cause proliferation and differentiation of dendritic cells, recruits dendritic cells into the tumor microenvironment.[12-14] Herpes simplex virus-thymidine kinase (HSV1-TK) is an enzyme that phosphorylates the antiviral prodrug valacyclovir and converts it into a nucleotide analog which causes cell death of mitotically active cells such as HGG.[9,15-17] By combining Flt3L and conditionally cytotoxic HSV1-TK, the infiltrating dendritic cells recruited into the tumor microenvironment become exposed to endogenous glioma antigens (released by HSV1-TK dependent tumor cell cytotoxicity), and become activated by TLR2 agonists, such as HMGB1; these dendritic cells then become capable of inducing specific anti-glioma immune responses against residual malignant glioma cells that remain post-surgical excision (Figure 1B).[18-22] In pre-clinical studies, this approach induced both T cell immune cytotoxicity, memory, and high therapeutic efficacy and eliminated a large percentage (i.e., 50-75%) of tumors in various mouse models of glioblastoma.[13,23-27] The safety of this dual vector treatment in humans has not been established previously, though its safety in rats, canines and marmosets has been tested earlier by us.[22,28-30] We hypothesize that the co-administration of Ad-hCMV-TK and Ad-hCMV-Flt3L viral vectors to the post-resection tumor bed followed by oral valacyclovir can be safely combined with standard of care chemoradiation in patients with newly diagnosed high grade gliomas, and will potentially stimulate an anti-HGG immune response.

Panel: Research in Context

Evidence before this study

We conducted a thorough search on PubMed to identify both preclinical and clinical studies related to the use of "Ad-TK AND Ad-Flt3L AND Glioma" as the search term. The search encompassed articles published between January 1st, 1993, and May 23rd, 2023. The results returned a total of 13 articles. The data surveyed strongly suggest that this particular approach holds promise in eliciting targeted immune responses against glioma in rats, dogs, and non-human primates (e.g., marmosets). These 13 articles were exclusively authored by our research group and primarily focused on preclinical models involving rodents, dogs, and primates. (Note: there is only one other team using Flt3L to treat pancreatic cancer –Hegde et al., Cancer Cell, 2020-, and one other group utilized a virus to express Flt3L in glioma in 2012 –Barnard et al., Neurosurgery, 2012-, yet never expanded that work further. We described the combined gene therapy in 2005 –Ali et al., Cancer Research 2005). Work from supporting 29 papers studying the effects of TK and Flt3L in various models of gliomas served as the background information that was submitted to FDA as the basis for the clinical evaluation of our approach in a phase 1 clinical trial (IND-14574; ClinicalTrials.gov: NCT01811992). The progress made in glioma treatment in recent years has been limited. Almost all clinical trials conducted thus far have failed to demonstrate clinical benefits for this devastating disease. Ad-HSV-TK has demonstrated the ability to induce infiltration of diverse immune cells, including macrophages and T cells, both in rodent models and clinical settings. However, the immune response against the glioma by Ad-HSV-TK/GCV therapy often falls short without additional immunostimulatory strategies. By incorporating the co-expression of Flt3L, Ad-HSV-TK/GCV treatment stimulates a very potent antitumor immune response in experimental settings. This co-expression of Flt3L has been proven to attract dendritic cells to the tumor microenvironment, resulting in enhanced antigen presentation and subsequent infiltration and activation of T cells in glioma animal models. The safety and efficacy of the combined treatment has not been reported in human patients.

Added value of this study

Brain tumors are poor stimulators of anti-tumor immune responses. We hypothesize that a lack of dendritic cells within the brain explains the absence of immune responses against brain tumors. Therefore, stimulating dendritic cell infiltration will cause a robust anti-tumor immune response. To the best of our knowledge, this study represents the first-in-human trial designed to test dual-vector (Ad-TK+Valacyclovir and Ad-Flt3L) administration within the resection cavity walls following surgical resection. Our approach involves the administration of Ad-HSV-TK, which expresses HSV1-TK, an enzyme that phosphorylates the prodrug Valacyclovir, leading to its cytotoxicity towards dividing tumor

cells. We also administered the Ad-Flt3L, which expresses the cytokine Flt3L to recruit dendritic cells to the brain and activate them. Upon killing of dividing tumor cells, the release of damage associated molecular patterns, such as HMGB1, triggers the activation of dendritic cells through TLR2. Additionally, dendritic cells take up tumor antigens. Consequently, activated dendritic cells carrying tumor antigens migrate to lymph nodes to initiate a T-cell mediated anti-glioma immune response. Immunophenotyping of tumor biopsies obtained before dual vector administration revealed scarce infiltration of cytotoxic CD8+ cells, with myeloid and Tregs being the most abundant immune populations. These findings are consistent with glioma-induced immunosuppression. Paired biopsies obtained at first surgery and second surgery, i.e., following recurrence (i.e., after standard of care treatment and administration of the combined gene therapy) were obtained from eight patients. In these we could demonstrate evidence of immune infiltration by T cells and dendritic cells using multiplex immunocytochemistry. Furthermore, our data provide evidence of the biological activity and persistence of viral vector activity and transgene expression, as immunoreactivity for HSV1-TK (expressed by Ad-TK) was detected for up to 17 months post-vector injection. We detected HSV1-TK immunoreactivity in 5/8 patients. Notably, a 38.8% two-year survival rate was observed (compared to the current records showing 18% two-year survival rate), with one patient still alive nearly five years post-treatment. In addition, patients whose tumors express a mutated form of IDH1 live longer; none of the tumors in the patients in our trial expressed this mutated protein. These results support the further consideration of this approach in larger clinical trials.

Implications of all the available evidence

This dual-vector gene therapy approach has demonstrated safety and feasibility in treating challenging high-grade gliomas, which have historically shown resistance to conventional therapies. This strategy holds the potential of eliciting targeted anti-glioma immune responses against residual malignant glioma cells that persist after surgical resection. The long-term persistence of transgene expression (HSV1-TK) for up to 17 months post viral-vector administration suggests that continuous administration of Valacyclovir could augment the cytotoxic effect of Ad-HSV-TK and lead to more favorable patient outcomes. Importantly, this dual-vector approach can be safely combined with standard-of-care chemoradiation in patients with newly diagnosed high-grade gliomas. These findings not only have the potential to improve overall survival and quality of life but also warrant further investigation in larger phase 2 clinical trials.

Methods

Objectives

Our primary objective was to identify the maximum tolerated dose (MTD) of Ad-hCMV-Flt3L and Ad-hCMV-TK, administered into the tumor bed after maximal safe resection of malignant gliomas. The secondary objective was to assess the potential benefit of Ad-hCMV-TK and Ad-hCMV-Flt3L dual-vector treatment of primary malignant glioma in overall survival (OS) at 12- and 24-months from intra-operative diagnosis. Exploratory objectives included the study of histological indices of inflammatory responses in tumor tissue from subsequent resections, when available, as well as measures of potential surrogate markers of intracranial immune responses. Viral vectors were produced at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX. Examples of the last yearly quality control including the bioactivity of each vector is provided in the Supplemental Appendix [Figures S1 (Ad-hCMV-TK) and S2 (Ad-hCMV-Flt3L)].

Patient Population

Adult patients with presumed newly diagnosed HGG who underwent maximal safe resection at the University of Michigan were potentially eligible**.** Key inclusion criteria were ages 18-75, KPS ≥70, and suspected newly diagnosed HGG amenable to gross total resection. Out of 21 subjects consented, two failed to meet eligibility criteria. In Cohort B one subject became unevaluable due to early withdrawal, not due to study-related toxicity, and was replaced to keep the total number of patients in Cohort B = 3. Eighteen subjects in all were evaluable and received study treatment. The eligibility section of the Supplemental Appendix contains detailed inclusion and exclusion criteria, and the CONSORT flow diagram is provided in Figure S3 of the Supplemental Appendix.

Eligible subjects who provided informed consent underwent maximal safe resection as indicated in the study schema (Figure 1C). Once the intra-operative pathology consultation confirmed HGG, subjects were enrolled in a phase 1, open label, dose escalation safety study of Ad-hCMV-TK and Ad-hCMV-Flt3L, assigned to six escalating doses in a 3+3 design (Supplemental Appendix Table S1, and Figure S3). The starting dose was Ad-hCMV-TK $1x10^{10}$ vp and Ad-hCMV-Flt3L $1x10^{9}$ vp (Cohort A), and the doses were escalated respectively to $1x10^{11}$ vp and $1x10^{9}$ vp (Cohort B), $1x10^{10}$ vp and $1x10^{10}$ vp (Cohort C), $1x10^{11}$ vp and $1x10^{10}$ vp (Cohort D), $1x10^{10}$ vp and $1x10^{11}$ vp (Cohort E), and finally, $1x10^{11}$ vp and $1x10^{11}$ vp (Cohort F).

The dual vectors were administered in a total volume of 2 ml to the tumor bed, divided into 0.1 ml injections at 20 sites. This was followed by two 14-day cycles of oral valacyclovir 2g TID and standard-

of-care, upfront radiation and concurrent temozolomide per treating physician(s)**.** Valacyclovir courses started at 1-3 days and 10-12 weeks after vector administration. This approach is based on our animal data showing viral transgene expression up to 6 and 12 months post-delivery of adenovirus into the brain.[31,32] Dose modification for valacyclovir was permitted if deemed necessary by the investigator and approved by the medical monitor, as outlined in the supplemental methods section of the Supplemental Appendix. Please refer to Table S2 for detailed information on the dose modification guidelines, as well as the renal adverse event management algorithms for valacyclovir outlined in Table S3.

This clinical trial was reviewed and approved by the Institutional Review Board-MED (University of Michigan School of Medicine) and registered at ClinicalTrials.gov (NCT01811992). An IND was obtained from the FDA prior to the study initiation (BB-IND 14574).

Toxicity Evaluation

Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version v4.0. Any one of the following occurring within 21 days of dual vector administration was considered a dose-limiting toxicity (DLT): 1) Grade 4 toxicity for constitutional symptoms with the exception of fever > 40°C for ≤ 24 hours, 2) ≥ Grade 3 neurologic toxicity relative to the changes from the pre-treatment neurological status and attributable to the study therapy regimen, 3) ≥ Grade 3 or greater non-hematologic toxicity attributable to the study therapy regimen, and 4) ≥ Grade 2 or greater autoimmune events.[9,33,34] Additional detail in study design such as surgical, medical, and radiation protocols can be found in the supplemental methods section in the Supplemental Appendix.

Immunohistochemistry on paraffin embedded brain biopsies (IHC-DAB)

Resected tumor tissue from the primary resections, as well as available tissue from the second resections, were analyzed by immunohistochemistry, and by multiplex immunohistochemistry.[18,35-37] Brain sections were subjected to endogenous peroxidase quenching carried out using a 0.3% H_2O_2 incubation for 5 minutes at room temperature, followed by heat-induced antigen retrieval, performed using 10 mM citric acid, 0.05% Tween 20, pH 6.0. Tissue permeabilization and blocking were completed using PBS 0.2% Tween-20 with 5% normal goat serum for one hour at room temperature. Tissue was then incubated with primary antibodies at 4°C overnight with concentrations as indicated: CD45 (Cell signaling #13917, 1:1000), CD3e (Cell signaling #85061, 1:400), CD11c (Cell signaling #45581, 1:1000), CD68 (Abcam ab955, 1:200), CD19 (Cell signaling #90176, 1:400), CD8 (Leica NCLL-CD8-4B11, 1:100), CD4 (Cell signaling # 48274, 1:500), HSV1-TK (In house, 1:1000), GFAP (Millipore #AB5541, 1:500), and SOX2 (ThermoFisher #MA5-31456). Sections for IHC-DAB detection were then incubated with biotinylated

secondary antibodies at a 1:1000 dilution in PBS with 0.2% Tween-20 overnight at 4°C (Polyclonal Goat Anti-Rabbit Immunoglobulins/Biotinylated, Dako E0464, or Polyclonal Goat Anti-Mouse Immunoglobulins/Biotinylated, Dako E0433). Avidin-Biotin-Complex (ABC) Binding reagent (Vectastain Elite ABC kit) and Betazoid DAB Chromogen detection kit (BioCare BDB2004) were used according to the manufacturer's instructions. The IHC-stained slides were digitized at a single focal plane level at 40X magnification. Positive cells in the whole sections were quantified using QuPath v. 0.3.0. Sections for immunofluorescence detection were incubated with conjugated secondary antibodies at a dilution of 1:1000 Donkey anti-Rabbit IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 555 (ThermoFisher #A-31572), Donkey anti-Chicken IgG (H+L) Alexa Fluor 647 (Jackson ImmunoResearch # 703-605-155), and Donkey anti-Mouse IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 488 (ThermoFisher # A-21202). Details of the multiplex immunocytochemistry and statistical analysis are provided in the Supplementary Methods, in Correlative Studies within the Supplemental Appendix.

HSV1-TK detection specificity

To determine the *in situ* specificity of HSV1-TK detection, we infected the human glioma cell line SJGBM with Ad-TK or Ad-βGal (MOI=100) and fixed the cells with PFA 48 hours after infection. We then incubated the antibody solution of HSV1-TK (1:1000) for 24 hours with fixed, permeabilized infected cells to obtain: (1) antibody solution pre-absorbed against cells infected with Ad-βGal, and (2) antibody solution pre-absorbed against cells infected with Ad-TK. We expected that antibody pre-absorbed with Ad-βGal would not recognize any elements from the viral infection, but would recognize the HSV1-TK antigen, while antibodies pre-absorbed against cells infected with Ad-TK would not recognize any HSV1-TK present in the human samples. We employed the pre-adsorbed antibody solutions for IHC using the DAB method, or immunofluorescence as described in the Immunohistochemistry on Paraffin-Embedded Brain Biopsies (IHC-DAB) section.

Statistical Analysis

Demographic data was summarized in a tabular format. Kaplan-Meier method was used to estimate median, 12- and 24-months overall survival along with 95% confidence intervals. Overall survival was defined from the time of study enrollment (the date of dual vector injection) to the time of death. Progression-free survival was defined from the time of study enrollment to the time of first progression or death using iRANO criteria. RStudio Version 1.3.1073 was used for statistical analysis.

This trial is registered with ClinicalTrials.Gov, NCT01811992.

Role of Funding Source

The study's funders played no role in the design, collection, analysis, interpretation of data, or the writing of the manuscript. Authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication.

Results

Patients Characteristics

Eighteen patients with median age of 64 years (range 45-73) were assigned to six dose levels. As summarized in Table 1A, eight subjects were women (44%). The KPS at the time of enrollment was 90-100 in fifteen subjects (83%), 70-80 in three subjects (17%). In eleven participants (61%) radiographic gross total resection was achieved prior to the dual vector administration. All participants met the inclusion criteria of having the intraoperative pathology diagnosis of high-grade glioma. Final diagnosis was as follows: 17 tumors (95%) were diagnosed as glioblastoma, WHO grade 4 (3 of them were of the gliosarcoma subtype), and one was an anaplastic astrocytoma, WHO grade 3 glioblastoma (5%). All tumors were IDH wildtype, and 39% (n=7) had MGMT promoter methylation. Comprehensive information regarding the baseline demographic and clinical characteristics of each patient is provided in Table S4 of the Supplemental Appendix.

Study Treatment Tolerability

Six subjects (33%) experienced adverse events that were at least possibly related to study treatment which ranged from CTCAE grades 1 to 3 (Table 1B) and consisted of one subject per following toxicities: dyspepsia (grade 1), elevated creatinine (grade 2), dizziness (grade 1), encephalopathy (grade 3), headache (grade 1), seizure (grade 2 & 3), confusion (grade 2), hallucinations (grade 1), acute kidney injury (grade 3), and maculo-papular rash (grade 1).

Ten subjects experienced serious adverse events (Table S5 of the Supplemental Appendix) which ranged from CTCAE grades 2 to 5. Serious adverse events in all but one subject were deemed unrelated to the study treatment. One subject experienced three serious adverse events of grades 2-3, which were possibly related to study treatment. Serious adverse events possibly related to the study treatments were grade 2 seizure (n=1), grade 3 encephalopathy (n=1), and grade 3 acute kidney injury (n=1), all in the same patient, which were possibly related to valacyclovir. No dose-limiting toxicity of the dual viral vectors was observed, and the maximal tolerated dose of HSV-TK and Flt3L vectors was not reached. Other adverse events which were unrelated to study treatments are summarized in Table S6 of the Supplemental Appendix; (see also supplemental methods: Toxicities and Dose Delays).

Upfront Treatment (see also Supplemental Appendix: Protocol Treatment Plan)

Study subjects received upfront radiation and concurrent temozolomide per standard of care by treating oncologists. Detail of adjuvant treatment rendered was available for 17 subjects. Details of standard of care chemoradiation for one subject who elected to receive care closer to home were unavailable. The one

patient with anaplastic ependymoma received a total 59.4 Gy of radiotherapy without concurrent temozolomide followed by imaging surveillance without adjuvant chemotherapy.

Of 16 patients with glioblastoma with known radiation details, all received concurrent temozolomide, 14 patients received the standard total 60 Gy, one patient received hypofractionated 40.5 Gy total, and one patient received 10 Gy before interruption due to wound issues and later completed 40.5 Gy between adjuvant temozolomide cycles. All 16 patients received standard-of-care sequential adjuvant cyclic temozolomide (range 1-11 cycles total). One patient received bevacizumab shortly after completion of concurrent chemoradiation for disease burden from post-radiation treatment changes along with cyclic temozolomide. None of the subjects opted to use tumor treating fields as part of the upfront treatment.

Surgical Pathology at Suspected Recurrence

The timing of subsequent surgeries in relation to radiographic progression is illustrated in Figure 2B. Eight patients (44%) underwent at least one subsequent resection. After the dual vector and valacyclovir therapy and upfront standard of care therapy, seven patients had re-operation at the time of radiographically suspected tumor progression; six subjects had surgically confirmed progression though the resected tissues from three of these subjects had extensive treatment related inflammation and necrosis, and <50% was tumor; one subject (ID 7) had surgically confirmed pseudoprogression. Pseudoprogression was defined as ≤ 5% proliferating tumor involvement of resected tissue. One other subject (ID 5) received second line therapy without surgical confirmation of first progression but underwent re-resection after the second line therapy, at which time pseudoprogression was noted.

When further progressions were suspected, four subjects (ID 1, 2, 8, 21) underwent additional resections; three had two re-resections (ID 1, 8, 21), and one subject had three re-resections (ID 2). Subject ID 1, 8, and 21 had surgical confirmation of progression after first-line therapy but only <50% tumor involvement of the resected tissue; subject ID 1 (Figure 3A) and 21 had similar findings at subsequent re-resection with majority of the resected tissue showing treatment related changes albeit confirmed progression (tumor >5%); subject ID 8 had surgically confirmed pseudoprogression after the second-line therapy of procarbazine and lomustine.

Subject ID 2 had the diagnosis of anaplastic ependymoma from the tissue obtained from the initial surgery prior to the dual vector injections, and the first surgically confirmed local recurrence showed recurrent/residual anaplastic ependymoma. Subsequently, this patient developed a contralateral distant lesion which was biopsied and showed high grade glioma that was morphologically different from the

original anaplastic ependymoma. This lesion was then resected two months later, which was notably more infiltrative than the original tumor at the initial diagnosis, with features of astrocytoma with areas of necrosis and microvascular proliferation consistent with glioblastoma. It was unclear if this distant lesion was a new primary tumor or a dedifferentiation of the known anaplastic ependymoma.

Progression-Free and Overall Survival

The median overall survival (OS) from the time of enrollment was 21.3 months (95%CI: 11.1, 26.1). The 12-month OS was 72% (95%CI: 45.6, 0.87) and the 24-month OS was 38.8% (95%CI: 17.5, 60.0). (Figure 2A). The median progression free survival was 9.9 months (95%CI: 7.3, 13.3). Notably, the three-year survival rate was 16.66% (3/18 patients), the four-year survival rate was 11.11% (2/18 patients), and one patient is still alive 57 months after enrollment (Patient 16). (See also Supplemental Appendix, page 10, Clinical and Imaging Evaluation)

Pre-operative diffusion-weighted imaging (DWI) (n=9) and dynamic susceptibility contrast-enhanced (DSC) (n=18) parameters were evaluated. There were weak positive correlations between baseline pre-operative nrCBV and OS, and between pre-operative nADC mean and OS (r = 0.53 and 0.49, respectively). No significant correlations were found between MRI parameters and survival (OS or PFS). MRI results are discussed in Supplementary Results within the Supplemental Appendix.

Immunocytochemistry Analyses

Immunohistochemical analysis of immune infiltrating cells was performed on tumor sections at primary resection, i.e., pre vector TK-Flt3L treatment, and compared with the same patient's samples taken at secondary surgery due to potential tumor recurrence (n=8). There were no differences in: hematopoietic CD45 positive cells (Figure S4), or monocytic lineage cells (CD68 positive cells) (Figure S5).

Importantly, CD3e positive cells (T-lymphocytes) were significantly increased in the re-resection sample (surgery 2), in comparison with primary resection (surgery 1) ($p<0.0001$, Figure 3B-D). Deeper characterization of T-cells showed that there was no difference in CD4+ cells (Figure S6), while there was a statistically significant increment of CD8+ cells ($p<0.0001$, Figure 3E-G) in surgery 2 samples.

Multiplex Immunocytochemistry Analysis

Multiplex immunohistochemical analysis of the tumor microenvironment was performed on tumor sections at primary resection, prior to administering adenoviral vectors expressing either HSV1-TK or

Flt3L, and then compared data with the same patient's samples obtained during secondary surgery due to presumptive tumor recurrence (n=8). Analysis revealed no differences in cDCs/monocytes, double negative T cells, CD4+ T cells, cytotoxic CD4+ T cells, Regulatory T cells (Tregs), macrophages, or "other leukocytes" (CD45+ cells not expressing any other immune markers) (Figure S7B-H). However, the analysis showed statistically significant increases in CD8+ T cells ($p<0.0001$), pDCs ($p<0.0001$), double positive T cells ($p<0.01$), and cytotoxic CD8+ T cells ($p<0.05$) when comparing data from surgery 1 to data from surgery 2, (post-radiotherapy, chemotherapy, and gene therapy (Figure 4H-K). The co-localization of CD45 and HLA-DR expression was utilized to identify pDCs (Figure S8A), while the co-localization of CD45, CD3e, CD8, and CD4 expression was employed to identify double positive T cells (Figure S8B). CD8+ T cells were identified by co-localization of CD45, CD3e, and CD8; cytotoxic CD8+ T cells were identified by co-localization of these three markers, plus the additional co-localization of Granzyme B or CD107a (Figure S8C).

Neighborhood Analysis

After clustering neighborhoods (as defined in Supplementary Methods: Correlative Studies, within the Supplemental Appendix) with similar compositions into regions using CytoMAP, three distinct regions were identified in all tissue samples: the Immune Region, the Tumor Region, and the Other Region. The Immune Region, shown in gold in Figure 4A-C and in Supplemental Appendix (Figure S9 and Figure S10), was defined by a high density of CD45+ cells compared to the rest of the tissue. The Tumor Region, shown in teal in Figure 4A-C and Figure S9-S10, was defined by a high density of SOX2+ cells compared to the rest of the tissue. The Other Region, shown in purple in Figure 4A-B and Figure S9-S10, was characterized by a high density of cells that were both SOX2- and CD45-, making them impossible to phenotype using the scheme used. Across all patients analyzed, the Tumor Region (enriched in SOX2+ cells) decreased in size by 36.5 ± 10.7% (range 3.6-47.4%; n=8). In contrast, the Immune Region (enriched in CD45+ cells) increased in six patients by 21.98 ± 5.6% (n=6), while it decreased in two patients by 18.1%, and 23.6%. On average, the Tumor Region accounted for a smaller proportion of the analyzed tissue, while the Immune Region expanded (Figure 4D). Analysis of region composition, or average number of cells per neighborhood within a region, showed that within the Tumor Region, the density of various immune cell types increased in samples obtained from the second surgical resection. These immune cell types included CD8+ T cells, double positive T cells, cDCs/monocytes, and pDCs (Figure 4F-G).

Bioactivity of the viral gene therapy vectors: persistence of HSV1-TK immunoreactivity, and increase in circulating level of Flt3L post dual-vector administration

We aimed to demonstrate the long-term expression of HSV1-TK and increase in Flt3L production in patients who received the dual-vector TK-Flt3L treatment through the analysis of biopsies and serum samples, respectively. In total, eight patients underwent two surgeries, and we found HSV1-TK positive cells in five of them through immunofluorescence and IHC. The longest period of expression was observed in patient #21, who exhibited expression for 17 months after treatment administration (Figure 5A and Figure S12). We validated the immunodetection's specificity by performing pre-absorption of antibodies with Ad-TK infected cells; this eliminated the detection of HSV1-TK immunoreactivity as shown in Figure 5B and Figure S13. Further analysis of HSV1-TK immunoreactive cells at tumor recurrence showed three types of cells: tumor cells (cells that are positive for HSV1-TK+, SOX2+, and GFAP+), glial/astrocyte cells (cells that are HSV1-TK+, GFAP+ and SOX2-), and neurons, which were HSV1-TK+, GFAP- and SOX2-, and displayed typical neuronal morphologies of dendrites and axons (Figure 5C). We note that the continued presence of HSV1-TK expression in tumor cells supports the administration of Valacyclovir over longer time periods in future clinical trials.

To detect potential activity from the Ad-Flt3L vector, we measured the patients' circulating level of Flt3L before (initial screening, pre-surgery) and two weeks after viral administration (Figure 5D). The results show that Flt3L circulating levels two weeks after treatment were statistically significantly higher than the initial value ($p=0.004$). These data supports the hypothesis that the increase in Flt3L circulating levels in the patients is due to the expression from vectors injected into the brain.

Anti-adenovirus antibodies

Neutralizing anti-adenovirus antibody titers were tested in cohorts B through F (n=15) and the results summarized in Figure S14 of the Supplemental Appendix. The baseline anti-adenovirus antibody titers prior to dual viral vector injection were between <2 to 2048. Specifically, five patients had no circulating anti-adenovirus neutralizing antibodies (titer ≤ 2) at basal levels before delivery of vectors; four patients had titers between 8-64; and two patients had high basal levels (512-2048). All patients who were evaluated serially showed a significant increase in their antibody titer following the delivery of the viral vector. ($p=0.0005$).

Discussion

We report on the first-in-human phase 1 clinical trial of dual cytotoxic and immune-stimulatory adenoviral vector administration combined with standard-of-care consisting of maximally safe resection followed by chemoradiation and adjuvant chemotherapy. The treatment was well tolerated, with no dose limiting toxicity attributable to the administration of adenoviral vectors. There were occasional mild to moderate toxicities that were possibly related to valacyclovir; thus, reduced dose of valacyclovir in future studies may be a consideration. An early study of adenovirus injected into the tumor cavity post-surgical excision found toxicity at $2x10^{12}$ pfu injected.[10] Since this study, trials using adenoviral vectors, including ours, have remained one log below this dose, and consequently MTDs were not reached.

The tissue obtained at tumor recurrence (and post-dual vector TK-Flt3L treatment), showed an increase in CD8+ T cells as revealed by immunocytochemistry. The finding was further confirmed by spatially resolved multiplex immunocytochemistry, which showed an increase in CD8+ T cells expressing activation markers granzyme B and CD107a. Additionally, there was a significant increase in double positive T cells, which could be pro- or anti-tumor.[38] An increase of pDCs was also observed, which was consistent with our preclinical findings.[14,39] Notably, there were no significant differences found in macrophages or FoxP3+ regulatory T cells (Tregs) between the primary tumor and tumor recurrence when all eight patients were considered together. However, five out of eight patients demonstrated reduced proportions of Tregs in their recurrent tumor microenvironment (TME), as depicted in Supplemental Appendix (Figure S7G). Though these results do not agree with previous findings on the TME of GBM at recurrence (which demonstrated a substantial decrease in glioma-associated macrophages[40] and an increase in Tregs[41]) they may be a result of our gene therapy, and thus indicate the induction of a hot TME. While some studies have reported an increase in CD8+ T cells at recurrence in response to SOC,[42,43] the magnitude of increase seen in our trial is numerically higher. As an example, in the study conducted by Mohme et al.,[42] they reported a 5% increase in CD8+ T cells within the tumor infiltrating lymphocyte compartment upon recurrence. Our results indicate an increase of 28%. By quantifying the subsets of immune cells and conducting a cell neighborhood analysis, we demonstrate that immune infiltration occurs both around and within regions densely populated with tumor cells. Additionally, Treg and macrophage populations in the tissues examined did not increase, which differs from literature data indicating that they increase at recurrence. Thus, our data appear to be qualitatively different from previous assessments, a difference that could be due to the administration of our viral vectors. However, macrophages could still become immunosuppressive, and thus inhibit the anti-glioma immune response. Our cell-cell correlation analysis demonstrates an increased interaction of macrophages with T cells at

surgery 2 (Supplemental Appendix, Figure S11), potentially suggesting that immunosuppressive macrophages could reduce the therapeutic impact of the increased number of CD8+ T cells and pDCs, as recently described.[44,45]

Although this study was not powered for survival analysis, the median overall survival of 21.3 months (95%CI: 11.1, 26.1) is promising, especially considering that glioblastoma has a known historical overall survival rate of 16-18 months, though high complexity centers report survivals of 19-21 months.[46] Remarkably, the two-year survival rate was 38.8% (7/18 patients), the three-year survival rate 16.66% (3/18 patients), and the four-year survival rate was 11.11% (2/18 patients); one patient is still alive 57 months after vector administration (patient 16). Future directions may consider the inclusion of immune checkpoint blockage[47] and/or methods to reduce the strong immunosuppressive glioma microenvironment. Since the modern dawn of gene therapy in the 70's there have been close to sixty viral gene therapy trials for brain tumors using adenoviral vectors (~20 trials), HSV1 vectors (~12 trials), retroviral vectors (~6 trials), and measles virus, Newcastle Disease virus, vaccinia, reovirus, Parvovirus-H1, and Poliovirus-derived vectors.[8] Viral vectors have been used to deliver conditional cytotoxicity, oncolysis, cytokines, and the use of checkpoint inhibitors in combination with various viral vectors.[8] In gene therapy trials, clinical outcomes have been less impressive than expected, with only small numbers of patients displaying long-term survival. A recent publication utilizing up to six repeated injections of intratumoral oncolytic HSV-G47Δ injections for the treatment of residual or recurrent glioblastoma in a phase 2 trial reported promising one year survival rates.[48]

Correlative studies have yielded more promising results, with several indicating an increase in immune cells within areas of the brain/tumor that had previously been treated with gene therapy vectors, potentially transforming "cold" tumors into "hot" ones.[49,50] Our analysis of cellular neighborhoods and spatial phenotyping also revealed a significant increase in immune cell infiltration during the second surgery as compared to pre-treatment biopsies. In fact, five out of the eight consecutive biopsies showed immune infiltration, successfully converting "cold" GBM to "hot" and inflamed, as illustrated in Figure 4E and Supplemental Appendix (Figure S9-S11).

We detected an increase in circulating antibody titers following the delivery of the viral vector ($p=0.0005$). This indicates that following peri-tumoral injection of adenoviral vectors it is possible for the humoral immune response to increase. There was no correlation between vector dose, serum antibody levels, overall survival, or intracranial quantitative immune responses measured by immunohistochemistry.

In our trial, we extended the administration of the HSV1-TK substrate, valacyclovir, to two cycles. The rationale for extending the administration of valacyclovir is based on preclinical data demonstrating that in rodents, adenoviral vector mediated transgene expression can last up to one year.[31,32] As the cytotoxic effect is only realized during the administration of valacyclovir and tumor cell division, it might be sensible to further extend valacyclovir administration to increase the cytotoxic potential of the HSV1-TK/valacyclovir combination. Additionally, it could be equally important to consider multiple vector administrations, as recently described.[48]

Remarkably, biopsies obtained at tumor recurrence showed persistent expression of HSV1-TK up to 17 months post dual-vector administration. Five out of eight patients displayed HSV1-TK immunoreactive cells in tissue obtained from surgeries on tumor recurrences, and increased levels of circulating Flt3L were observed two weeks after treatment. These findings support the use of extended administration of Valacyclovir in a phase 1b/2 clinical trial. The sustained expression of the dual vector TK-Flt3L may be a mechanism for maintaining disease control over a prolonged period, as it stimulates systemic antitumor immunity. The continued increase in the amount of T cells and dendritic cells at second surgeries suggests that such an immune response might be at work. Both the longevity of transgene expression, and the increase of immune cells, corroborates our preclinical data.[12,14,18,20,23,27] The promising survival data and recruitment of immune cells, along with the persistent transgene expression from the vectors, suggest that this treatment approach may have significant potential for the management of the disease and warrants further investigation in a phase 1b/2 clinical trial.

Ethics Statement

We have obtained ethics approval from the Institutional Review Board-MED at the University of Michigan School of Medicine before enrollment (HUM00057130). The trial has been registered at ClinicalTrials.gov (NCT01811992). Prior to the initiation of the study, we obtained an Investigational New Drug (IND) from the FDA (BB-IND 14574). All patients provided pre-operative consent, and definitive enrollment occurred intraoperatively after confirming the presence of malignant glioma through Pathology examination. The most recent version of the Clinical Protocol can be accessed in the study protocol document.

Authors' contributions

Conceptualization and Study Design: MGC and PRL. Patients' enrollment and treatment: YU, DO, LJ, JH, OS, DL, AM, SHJ, WA, TH, KS, and KM. Neuropathology: SCP, APL, PM, and SV. Radiotherapy: MMK, DRW, and TL. Exploratory immunological and histopathological analysis: MLV, MEJW, SMF, AC, DZ, VNY, PD, MGC, and PRL. Figures: YU, MLV, MEJW, SMF, AC, MGC, and PRL. Data curation: YU, MLV, MEJW, SMF, AC, DA, RK, MGC, and PRL. Statistical analysis: YU, and LZ. Analysis and data interpretation: YU, LJ, AM, MLV, MEJW, SMF, AC, LZ, MGC, and PRL. Writing-original draft: YU, SMF, MGC, and PRL. Writing- review and editing: All authors thoroughly reviewed the data, made valuable contributions to the development of the manuscript, and provided their approval for the final version to be published. Data Validation: YU, MLV, MEJW, SMF, AC, LZ, MGC, and PRL. Fund Raising: MGC and PRL.

Declaration of interest

All authors hereby declare that they have no competing interests to disclose.

Acknowledgements

Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai Medical Center, and The Rogel Cancer Center at The University of Michigan.
[clinicaltrials.gov: NCT01811992]. We express our sincere gratitude to the patients and their families for their invaluable participation in this trial.

References

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-1251. DOI: 10.1093/neuonc/noab106.
2. Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16(8):2443-9. DOI: 10.1158/1078-0432.CCR-09-3106.
3. Maatta AM, Samaranayake H, Pikkarainen J, Wirth T, Yla-Herttuala S. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 2009;9(5):356-67. DOI: 10.2174/156652309789753365.
4. Castro MG, Candolfi M, Wilson TJ, et al. Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther 2014;14(9):1241-57. DOI: 10.1517/14712598.2014.915307.
5. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005;12(4):585-98. DOI: 10.1016/j.ymthe.2005.07.357.

6. Longo DL, Baden LR. Exploiting Viruses to Treat Diseases. N Engl J Med 2018;379(2):194-196. DOI: 10.1056/NEJMe1807181.
7. Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. Br J Cancer 2018;119(10):1171-1181. DOI: 10.1038/s41416-018-0258-8.
8. Banerjee K, Nunez FJ, Haase S, et al. Current Approaches for Glioma Gene Therapy and Virotherapy. Front Mol Neurosci 2021;14:621831. DOI: 10.3389/fnmol.2021.621831.
9. Wheeler LA, Manzanera AG, Bell SD, et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. Neuro Oncol 2016;18(8):1137-45. DOI: 10.1093/neuonc/now002.
10. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1(2):195-203. DOI: 10.1006/mthe.2000.0030.
11. D'Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K. Brain dendritic cells: biology and pathology. Acta Neuropathol 2012;124(5):599-614. DOI: 10.1007/s00401-012-1018-0.
12. Ali S, Curtin JF, Zirger JM, et al. Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 2004;10(6):1071-84. DOI: 10.1016/j.ymthe.2004.08.025.
13. Mineharu Y, King GD, Muhammad AK, et al. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res 2011;17(14):4705-18. DOI: 10.1158/1078-0432.CCR-11-0915.
14. Candolfi M, King GD, Yagiz K, et al. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia 2012;14(8):757-70. DOI: 10.1593/neo.12794.
15. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3(12):1354-61. DOI: 10.1038/nm1297-1354.
16. Sasaki M, Plate KH. Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Ann Oncol 1998;9(11):1155-66. DOI: 10.1023/a:1008488709359.
17. Castro MG, Lowenstein PR. Neuro-oncology: The long and winding road--gene therapy for glioma. Nat Rev Neurol 2013;9(11):609-10. DOI: 10.1038/nrneurol.2013.198.
18. Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 2005;65(16):7194-204. DOI: 10.1158/0008-5472.CAN-04-3434.
19. Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009;15(13):4401-14. DOI: 10.1158/1078-0432.CCR-09-0155.
20. Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009;6(1):e10. DOI: 10.1371/journal.pmed.1000010.
21. King GD, Kroeger KM, Bresee CJ, et al. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther 2008;16(4):682-90. DOI: 10.1038/mt.2008.18.
22. King GD, Muhammad AK, Curtin JF, et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 2008;10(1):19-31. DOI: 10.1215/15228517-2007-045.

23. Ghulam Muhammad AK, Candolfi M, King GD, et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 2009;15(19):6113-27. DOI: 10.1158/1078-0432.CCR-09-1087.
24. King GD, Muhammad AG, Larocque D, et al. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. 2011;19(10):1793-1801.
25. Muhammad AK, Puntel M, Candolfi M, et al. Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther 2010;88(2):204-13. DOI: 10.1038/clpt.2009.260.
26. Muhammad AK, Xiong W, Puntel M, et al. Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Hum Gene Ther Methods 2012;23(4):271-84. DOI: 10.1089/hgtb.2012.060.
27. Alghamri MS, McClellan BL, Avvari RP, et al. G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv 2021;7(40):eabh3243. DOI: 10.1126/sciadv.abh3243.
28. VanderVeen N, Paran C, Appelhans A, et al. Marmosets as a preclinical model for testing “off-label” use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. 2014;1:10.
29. Xiong W, Candolfi M, Liu C, et al. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. 2010;5(6).
30. Candolfi M, Pluhar GE, Kroeger K, et al. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol 2007;9(3):245-58. DOI: 10.1215/15228517-2007-012.
31. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999;5(11):1256-63. DOI: 10.1038/15207.
32. Zermansky AJ, Bolognani F, Stone D, et al. Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS. Mol Ther 2001;4(5):490-8. DOI: 10.1006/mthe.2001.0479.
33. Chiocca EA, Aguilar LK, Bell SD, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol 2011;29(27):3611-9. DOI: 10.1200/JCO.2011.35.5222.
34. Desjardins A, Gromeier M, Herndon JE, 2nd, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. N Engl J Med 2018;379(2):150-161. DOI: 10.1056/NEJMoa1716435.
35. Nunez FJ, Mendez FM, Garcia-Fabiani MB, et al. Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures. J Vis Exp 2019(143). DOI: 10.3791/58931.
36. Nunez FJ, Mendez FM, Kadiyala P, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med 2019;11(479). DOI: 10.1126/scitranslmed.aaq1427.
37. Comba A, Faisal SM, Dunn PJ, et al. Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. Nat Commun 2022;13(1):3606. DOI: 10.1038/s41467-022-31340-1.

38. Overgaard NH, Jung JW, Steptoe RJ, Wells JW. CD4+/CD8+ double-positive T cells: more than just a developmental stage? J Leukoc Biol 2015;97(1):31-8. DOI: 10.1189/jlb.1RU0814-382.
39. Curtin JF, King GD, Barcia C, et al. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol 2006;176(6):3566-77. DOI: 10.4049/jimmunol.176.6.3566.
40. Fu W, Wang W, Li H, et al. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma. Front Immunol 2020;11:835. DOI: 10.3389/fimmu.2020.00835.
41. Sayour EJ, McLendon P, McLendon R, et al. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 2015;64(4):419-27. DOI: 10.1007/s00262-014-1651-7.
42. Mohme M, Schliffke S, Maire CL, et al. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes. Clin Cancer Res 2018;24(17):4187-4200. DOI: 10.1158/1078-0432.CCR-17-2617.
43. Maddison K, Graves MC, Bowden NA, et al. Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma. Oncotarget 2021;12(21):2177-2187. DOI: 10.18632/oncotarget.28069.
44. Hara T, Chanoch-Myers R, Mathewson ND, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 2021;39(6):779-792 e11. DOI: 10.1016/j.ccell.2021.05.002.
45. Chanoch-Myers R, Wider A, Suva ML, Tirosh I. Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis. Genome Med 2022;14(1):106. DOI: 10.1186/s13073-022-01109-8.
46. Pace A, Tanzilli A, Benincasa D. Prognostication in brain tumors. Handb Clin Neurol 2022;190:149-161. DOI: 10.1016/B978-0-323-85029-2.00001-4.
47. Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019;25(3):477-486. DOI: 10.1038/s41591-018-0337-7.
48. Todo T, Ito H, Ino Y, et al. Intratumoral oncolytic herpes virus G47 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 2022;28(8):1630-1639. DOI: 10.1038/s41591-022-01897-x.
49. Candolfi M, Yagiz K, Wibowo M, et al. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res 2014;20(6):1555-1565. DOI: 10.1158/1078-0432.CCR-13-2140.
50. Friedman GK, Johnston JM, Bag AK, et al. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. N Engl J Med 2021;384(17):1613-1622. DOI: 10.1056/NEJMoa2024947.

TABLE 1A: Patient Characteristics

Characteristic	Total N=18
Median age (range)	64 (45-73)
Women – no. (%)	8 (44)
KPS – no. (%)	
90-100	15 (83)
70-80	3 (17)
Radiographic GTR – no. (%)	11 (61)
MGMT methylated – no. (%)	7 (39)
IDH mutation – no. (%)	**0 (0)**
Final diagnosis – no. (%)	
Glioblastoma / Gliosarcoma	17 (94)
Anaplastic ependymoma	1 (6)

TABLE 1B: Adverse Events At Least Possibly Related to Study Treatment in Evaluable Patients

Event	Dual Vector Dose (N=3 per level)						Total
	A	B	C	D	E	F	N=18
	no.						*no. (%)*
Gastrointestinal disorders							
Dyspepsia, Grade 1	-	-	-	1	-	-	1 (6)
Investigations							
Creatinine increased, Grade 2	-	-	-	-	-	1	1 (6)
Nervous system disorders							
Dizziness, Grade 1	-	-	-	-	-	1	1 (6)
Encephalopathy, Grade 3	-	-	-	-	-	1*	1 (6)
Headache, Grade 1	-	-	-	1	-	-	1 (6)
Seizure, Grade 2	-	1*	-	-	-	-	1 (6)
Grade 3	1	-	-	-	-	-	1 (6)
Psychiatric disorders							
Confusion, Grade 2	-	-	-	-	-	1	1 (6)
Hallucinations. Grade 1	-	-	-	-	-	1	1 (6)
Renal and urinary disorders							
Acute kidney injury, Grade 3	-	-	-	-	-	1*	1 (6)
Skin and subcutaneous disorders							
Rash maculo-papular, Grade 1	-	1	-	-	-	-	1 (6)
Total no. patients with study related events	1	2	-	2	-	1	6 (33)

*Serious adverse events

Figure Legends

Figure 1: Overcoming lack of CNS dendritic cells by *in situ* immunotherapy using FLT3L and HSV1-TK. A) The central nervous system (CNS) lacks functional dendritic cells, thus resulting in failure to initiate effective immune response against high grade glioma (HGG). **B)** Using *in situ* immunotherapy with FLT3L at the tumor bed, a cytokine known to cause proliferation of dendritic cells, causes the migration of dendritic cells into the tumor microenvironment. By combining FLT3L and HSV1-TK, a cytotoxic vector, dendritic cells are recruited to choose tumor antigens within the glioma microenvironment and initiate systemic immunity, thus overcoming lack of CNS dendritic cells. **C)** In this study, adults with newly diagnosed HGG who underwent maximal safe resection received injection of HSV1-TK and Flt3L adenovectors to the tumor bed, followed by two 14-day cycles of valacyclovir and standard-of-care upfront chemoradiation.

Figure 2: Dual viral vector approach shows encouraging survival outcomes. A) Using Kaplan-Meier method, median overall survival was 21.3 months. **B)** Swimmer plots of bars representing each study subject's overall survival in months, noting those with steroid use at the time of enrollment. One patient with a rightward arrow is still alive and is currently followed for survival. Annotations correspond to respective timing of first progression and pseudoprogression per iRANO criteria (if known), and subsequent surgery with proportion of viable tumor noted in the sampled specimen. One patient had the diagnosis of anaplastic astrocytoma (**) and all other patients had the diagnosis of glioblastoma, including three with the gliosarcoma variant (*). All 18 subjects had the frozen pathology of malignant glioma prior to enrollment at the time of tumor resection.

Figure 3: Immunohistochemical analysis of CD3+ and CD8+ cells in human glioblastoma tissue at primary resection, pre-vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A) MRI of patient before primary resection (surgery 1) on date 4/7/14, Secondary surgery on date 7/16/14 and surgery 3 on 5/12/2021. **B and D**) Representative images of CD3 expression. Scale bar: 20 μm. **C)** Box plots and lines graphs represent the quantification of CD3+ cells numbers (cells/mm^2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-surgery upon recurrence (Surgery 2). Error bars represent ±SEM. n=8 patients, **** $p<0.0001$. **E and G**) Representative images of CD8 expression. Scale bar: 20 μm. **F)** Box plots and lines graphs represent the quantification of CD8+ cells numbers (cells/mm^2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-surgery upon recurrence (Surgery 2). Error bars represent ±SEM. n=8 patients, **** $p<0.0001$.

Figure 4: Neighborhood analysis of the tumor microenvironment in the biopsies obtained at primary tumor resection and post dual-vector TK-Flt3L treatment at tumor recurrence (see also Figure S9 and S10 of the Supplemental Appendix). The tumor microenvironment in glioblastoma tissues was analyzed at primary tumor resection and at tumor recurrence using a neighborhood approach. Neighborhoods of 50μm were raster scanned and clustered into three distinct regions. The cells of primary tumor resection tissue for patient 21 are shown in a plot colored by their region type **(A)**, while cells of recurrent tumor resection tissue for the same patient are shown in a plot **(B)**. The prevalence of the three region types within patient 21's samples is illustrated in a bar graph **(C)**, while the average region prevalence in tissues across all patients is shown in a bar graph **(D)**. Cellular re-organization of immunologically cold (surgery 1) into hot and inflamed gliomas (surgery 2) post dual-vector TK-Flt3L treatment is illustrated in **(E)**. Heatmaps displaying cluster composition (average number of cells per neighborhood within each region, log10 scale) of all cell types averaged across all primary tumor samples **(F)** and all recurrent tumor samples **(G)** are also presented. Additionally, quantification of CD8+ T cells out of total cells ($p < 0.0001$) **(H)**, pDCs out of total cells ($p < 0.0001$) **(I)**, double positive T cells out of total cells ($p < 0.01$) **(J)**, and cytotoxic CD8+ T cells out of total cells ($p < 0.05$) **(K)** is displayed in spaghetti plots for surgery 1 samples and surgery 2 samples.

Figure 5: Persistent expression of HSV1-TK and FLT3L post-dual vector TK-Flt3L treatment at tumor recurrence (see also Figure S12 and S13 of the Supplemental Appendix). A) Top panel illustrates the administration of viral therapy in the cavity after the initial tumor resection, which infects not only the infiltrating tumor cells but also the surrounding brain parenchyma comprising glial cells and neurons. HSV1-TK infected cells that divide in the presence of valacyclovir die; non-dividing cells such as neurons, or cells that did not divide during the valacyclovir cycles will remain alive and infected. Bottom panel shows the infected cells that did not die during the dual vector TK-Flt3L treatment are still to be present at tumor recurrence, as evidenced by the positive immunoreactivity for HSV1-TK (red) in the immunofluorescence analysis of patient #21's recurrent tumor biopsy 17 months following viral therapy administration. Five out of eight patients who had a second surgery showed a positive immunoreactivity for HSV1-TK (Figure S12). Nuclei are shown in blue (DAPI). **Panel B)** shows the same location of consecutive sections of surgery 2 of patient #21, where the specificity of the HSV1-TK antibody was tested by pre-absorbing it on (left section) infected cells with a control virus (βGal): Positive control; (middle section) infected cells with Ad-TK: Negative control, specific neutralization of the antibody while the right section shows the Hematoxylin and Eosin stain of the histology of the positive area (Lower magnification of the same area is shown in Figure S13). **Panel C**) presents the

immunostaining of the tissue obtained at tumor recurrence for HSV1-TK (red), GFAP (white), and Sox2 (green) of patient #21. Nuclei are shown in blue (DAPI). Yellow arrows point to cells (presumptive tumor cells) that are positive for HSV1-TK+, SOX2+ and GFAP+, white unfilled arrows point at HSV1-TK+, GFAP+ and SOX2- infected astrocytes, white filled arrows point at HSV1-TK+, GFAP- and SOX2- (possibly neurons). **D)** shows the expression of circulating level of FLT3L in the patients at initial screening and 2 weeks after treatment. The data analysis showed a significant increase in Flt3L levels after the dual vector TK-Flt3L treatment (***$p<0.001$).

Figure 1


A
Naïve glioma microenvironment
NO cytotoxity
T cells
HGG
NO tumor killing
NO release of tumor antigens & DAMPs
Lymph node
NO stimulation of adaptive anti-tumor immunity
B
Inflamed glioma microenvironment after gene therapy
HSV1-TK + Valacyclovir
Cytotoxity
HSV1-TK
Tumor killing
T cells
HGG
Release of tumor antigens & DAMPs
Dendritic cells
Lymph node
Flt3L
Antigen presentation
Dendritic cell recruitment & differentiation
Flt3L
C
Eligibility & Consent
Enrollment
Newly diagnosed suspected HGG
Age 18-75
KPS ≥ 70
GTR candidate
Frozen pathology confirmation
Dual Vector Injection
Surgery
1-3 days
Valacyclovir 2 g TID x 14 days
8-10 weeks
Valacyclovir 2 g TID x 14 days
SOC chemo-RT

Figure 2

A


Overall survival:
Median 21.3 months
12 months 72.2%
24 months 38.9%
All
Methylated
Unmethylated
Probability of Survival (%)
100
75
50
25
0
0
12
24
36
48
Months
Number at risk
18 17 13 11 7 4 3 2 2 1

B


Symbol Key:
* Gliosarcoma variant
** Anaplastic ependymoma
Steroid prior to study treatment
MGMT unmethylated
MGMT methylated
PD Progression of disease #1
PsP Pseudoprogression
Surgery (≥ 50% tumor)
Surgery (< 50% tumor)
Surgery (≤ 5% tumor)
Subject ID (Dose level)
Pt16 (E)
Pt02 (A)
Pt21 (F)
Pt08 (C)
Pt01 (A)
Pt05 (B)
Pt03 (A)
Pt07 (B)
Pt14 (D)
Pt11 (C)
Pt13 (D)
Pt18 (E)
Pt20 (F)
Pt12 (D)
Pt10 (C)
Pt15 (E)
Pt19 (F)
Pt06 (B)
0
12
24
36
48
60
Overall Survival in Months

Figure 3


A
Pre-surgery 1
Post-surgery 1
Pre-surgery 2
B
CD3+
20 µm
Surgery 1
C
****
CD3+ cell/mm2
600
400
200
0
Surgery 1
Surgery 2
D
CD3+
20 µm
Surgery 2
E
CD8+
20 µm
Surgery 1
F
****
CD8+ cells/mm2
600
550
500
450
400
100
50
0
Surgery 1
Surgery 2
G
CD8+
20 µm
Surgery 2

Figure 4


A
Patient 21- Surgery 1
1.7×10^4
1.2×10^4
7×10^3
2×10^3
y (µm)
0
6000
12000
x (µm)
B
Patient 21 - Surgery 2
1.7×10^4
1.2×10^4
7×10^3
2×10^3
y (µm)
0
6000
12000
x (µm)
C
Patient 21
Region Prevalence
100
50
0
% of tissue
S1
S2
D
All Patients (n=8): Region Prevalence Averages
Immune Region
Tumor Region
Other Region
Percentage of tissue (%)
100
50
0
S1
S2
E
Surgery 1
Surgery 2
Tumor Region
Immune Region
F
Immune Region
Tumor Region
Other Region
CD4+ T cells
CD8+ T cells
Cytotoxic CD4+ T cells
Cytotoxic CD8+ T cells
Double + T cells
Double - T cells
Tregs
cDCs/monocytes
pDCs
-1
-2
Surgery 1
G
Immune Region
Tumor Region
Other Region
CD4+ T cells
CD8+ T cells
Cytotoxic CD4+ T cells
Cytotoxic CD8+ T cells
Double + T cells
Double - T cells
Tregs
cDCs/monocytes
pDCs
-1
-2
Surgery 2
H
CD8+ T cells/total cells
****
SOX2- CD45+ CD3e+ CD4- CD8+ [GzB- and CD107a-]
0.2
0.015
0.010
0.005
0.000
1
2
Surgery
I
pDCs/total cells
****
SOX2- CD45+ CD3e- IBA1- HLA-DR+ CD11c-
0.04
0.03
0.02
0.01
0.00
1
2
Surgery
J
Double + T cells/total cells
**
SOX2- CD45+ CD3e+ CD4+ CD8+
0.010
0.004
0.0010
0.0005
0.0000
1
2
Surgery
K
Cytotoxic CD8+ T cells/total cells
*
SOX2- CD45+ CD3e+ CD4- CD8+ [GzB+ or CD107a+]
0.059
0.005
0.004
0.002
0.000
1
2
Surgery

Figure 5


A
Initial tumor
Tumor resection followed by viral therapy administration
Ad-TK
Ad-Flt3L
Glial cell
Neuron
Remaining tumor cell
TK-infected cells
Cell death
Dividing cells
+ Valacyclovir
Non-dividing cells
These cells will remain infected
Recurrent tumor
HSV1-TK
20 µm
Patient #21
17 months after viral vector administration
10 µm
B
Antibody pre-absorbed on Ad-βGal infected cells
Antibody pre-absorbed on Ad-TK infected cells
Hematoxylin and Eosin
C
HSV1-TK DAPI
GFAP DAPI
SOX2
HSV1-TK GFAP
HSV1-TK SOX2
HSV1-TK SOX2 GFAP DAPI
HSV1-TK+ SOX2+ GFAP
HSV1-TK+ GFAP+ SOX2-
HSV1-TK+ GFAP- SOX2-
D
Ad-Flt3L
Ad-Flt3L 10^11 vp
Ad-Flt3L 10^10 vp
Ad-Flt3L 10^9 vp
***
Flt3L (pg/mL)
Pre-surgery
Post-surgery (2 weeks)

Title: A non-randomized, open-label, dose-finding, first-in-human, trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injection.

Authors: Yoshie Umemura, M.D.[1], Daniel Orringer, M.D.[2], Larry Junck, M.D.[1], Maria L. Varela, Ph.D.[2,3,5], Molly E.J. West, M.S.[2,3,5], Syed M. Faisal, Ph.D.[2,3,5], Andrea Comba, Ph.D.[2,3,5], Jason Heth, M.D.[2], Oren Sagher, M.D.[2], Denise Leung, M.D.[1], Aaron Mammoser, M.D.[1], Shawn Hervey-Jumper, M.D.[2], Daniel Zamler, B.S.[2], Viveka N. Yadav, Ph.D.[2], Patrick Dunn, B.S.[2], Wajd Al-Holou, M.D.[2], Todd Hollon, M.D.[2], Michelle M. Kim, M.D.[6], Daniel R. Wahl, M.D., Ph.D.[6], Sandra Camelo-Piragua, M.D[7], Andrew P. Lieberman, M.D., Ph.D.[7], Sriram Venneti, M.D., Ph.D.[7], Paul McKeever, M.D., Ph.D.[7], Theodore Lawrence, M.D., Ph.D.[6], Ryo Kurokawa, M.D., Ph.D.[8], Karen Sagher[2], B.S.[2] David Altshuler, M.D.[2], Lili Zhao, Ph.D.[9], Karin Muraszko, M.D.[2], Maria G. Castro, Ph.D.[2,3,5], Pedro R. Lowenstein, M.D., Ph.D.[2,3,4,5].

Affiliations: [1]Depts. Of Neurology, [2]Neurosurgery, [3]Cell and Developmental Biology, [4]Department of Biomedical Engineering, [5]The Rogel Cancer Center, [6]Radiation Oncology, [7]Pathology, and [8]Radiology, The University of Michigan School of Medicine, and [9]Dept. of Biostatistics, The University of Michigan School of Public Health.

Acknowledgements: Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai Medical Center, and The Rogel Cancer Center at The University of Michigan.
[clinicaltrials.gov: NCT01811992].

Corresponding Author:
Pedro R. Lowenstein, M.D., Ph.D.
Address: 4570 MSRB II, Ann Arbor, MI 48109-0650
Email: pedrol@umich.edu
Phone: 734-764-0851

Running Head: Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma.

SUPPLEMENTAL APPENDIX

TABLE OF CONTENTS

Supplementary Methods: Eligibility 3

Supplementary Methods: Schedule of Assessments 5

Supplementary Methods: Protocol Treatment Plan 6

Supplementary Methods: Toxicities and Dose Delays 8

Supplementary Methods: Clinical and Imaging Evaluation 10

Supplementary Methods: Correlative Studies 11

Supplementary Results: MRI Studies 12

Table S1. Dual Viral Vector Dosing 14

Table S2. Dose Modification for Valacyclovir 15

Table S3. Renal Adverse Event Management Algorithm for Valacyclovir 16

Table S4. Patient Demographics and Baseline Characteristics 17

Table S5. All Serious Adverse Events 18

Table S6. Adverse Events Unrelated to Study Intervention 19

Table S7. Antibodies used in Multiplex Immunohistochemistry 20

Figure S1. Ad-hCMV-TK expresses bioactive transgene herpes simplex type 1 thymidine kinase (TK) 21

Figure S2. Ad-hCMV-Flt3L expresses its transgene human soluble FMS-like tyrosine kinase 3 ligand 22

Figure S3. The CONSORT flow diagram 23

Figure S4. Immunohistochemical analysis of CD45+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence 24

Figure S5. Immunohistochemical analysis of CD68+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence 25

Figure S6. Immunohistochemical analysis of CD4+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence 26

Figure S7: Phenotyping and quantification of immune cell types in the biopsies obtained at primary tumor resection and post dual-vector TK-Flt3L treatment at tumor recurrence. ...**Error! Bookmark not defined.**27

Figure S8: Multiplex immunocytochemical analysis of immune cells in the biopsies obtained post-dual vector TK-Flt3L treatment at tumor recurrence. 29

Figure S9: Neighborhood analysis of the tumor microenvironment in the biopsies obtained at primary tumor resection and at tumor recurrence. 31

Figure S10: Neighborhood analysis of the tumor microenvironment in glioblastoma tissues at primary tumor resection and at tumor recurrence. 33

Figure S11. Comparison of average cell-cell correlations across six patients exhibiting immune infiltration at tumor recurrence. 34

Figure S12: Persistent expression of HSV1-TK post dual-vector TK-Flt3L treatment at tumor recurrence. 35

Figure S13: Neutralization experiments to validate the specificity of HSV1-TK detection. 37

Figure S14: Detection of anti-adenovirus antibodies in plasma following dual vector treatment. ... 38

Supplementary References 39

Supplementary Methods: Eligibility

Inclusion Criteria

1. Newly identified supratentorial brain lesion compatible with a diagnosis of high-grade glioma (WHO III or IV) by MR with no prior treatment with either gene therapy, chemotherapy or radiation treatments that is amenable to attempted gross total resection (GTR). "High grade glioma" can include glioblastoma multiforme (WHO grade IV); gliosarcoma (WHO grade IV); anaplastic astrocytoma (WHO grade III); anaplastic oligodendroglioma (WHO grade III); and anaplastic ependymoma (WHO grade III).
2. Intraoperative histological frozen section analysis at the time of tumor resection shown to be compatible with high-grade glioma or malignant glioma (as described elsewhere throughout this document). If intraoperative diagnosis was not compatible with high grade glioma, the patient was not enrolled.
3. Karnofsky Performance Status (KPS) score ≥70
4. Laboratory values
5. CBC/differential obtained within 14 days prior, with adequate bone marrow function were defined as follows:
    1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
       Platelets ≥ 100,000 cells/mm3;
       Hemoglobin ≥ 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥10.0 g/dl is acceptable.);
    2. Adequate renal function, as defined below:
       BUN ≤ 30 mg/dl within 14 days prior.
       Creatinine ≤ 1.7 mg/dl within 14 days prior.
    3. Adequate hepatic function, as defined below:
       Bilirubin ≤ 2.0 mg/dl within 14 days prior.
       ALT/AST ≤ 3x laboratory upper limit of normal within 14 days prior.
6. Male and female; both genders must use contraception if of reproductive capacity
7. For women of childbearing potential, a negative pregnancy test performed within 14 days of surgery
8. Capable of informed consent
9. 18-75 years of age

Exclusion Criteria

1. Diffusely multifocal lesion
2. Lesions not amenable to GTR
3. Tumors infiltrating the cerebellum, bilateral corpus callosum ("butterfly glioma"), ventricular system, or brain stem
4. Infratentorial high grade glioma
5. Primary central nervous system (CNS) disease that would interfere with subject evaluation
6. Prior history of other cancer within five years except curative cervical cancer in situ, basal or squamous cell carcinoma of the skin
7. Evidence of other significant disease including hematologic, renal or liver disease that is not explained by the patient's current medical condition or concomitant disease
8. Patient known to have HIV, Hepatitis B, Hepatitis C
9. Active systemic infection
10. Immunosuppressive disorders (i.e., chronic steroid therapy, acquired or congenital immune deficiency syndromes, autoimmune disease)
11. Serious medical conditions (i.e., CHF, angina, diabetes mellitus Type 1, COPD, bleeding diathesis)
12. Any contraindication for undergoing MRI
13. Pregnant or lactating females
14. Unacceptable anesthesia risk
15. Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery
16. Prior gene therapy
17. Allergy to valacyclovir
18. Unable to take oral tablets

Supplementary Methods: Schedule of Assessments

	Screening (<14 days prior to surgery)	Day 0 (prior to surgery)	Day 0 (during surgery)	Day 2 ± 1 day	Week 2 ± 1 wk Neurosurgery visit	Week 1-3 NeuroOnc visit	Week 6 ± 2 wk	Week 10 ± 2 wk	Week 14 ± 2 wk	Week 18 ± 2 wk	12-Months Follow up[8]	24-Months Follow up[8]	Overall Survival[8]
Medical history	x				x	x	x	x	x	x			
Physical exam	x				x	x	x	x	x	x			
Karnofsky Performance Status	x				x	x	x	x	x	x			
Vital signs[1]	x	x				x							
Hematology[2]	x			x	x								
Clinical chemistry[3]	x			x	x								
MRI	x			x[5]			x	x	x	x			
ECG	x												
Pregnancy test (if applicable)	x	x				x	x	x	x	x			
Anti-Ad Abs	x				x		x	x					
Serum sample (stored)					x		x	x					
Blood sample (PMBC)	x				x		x	x					
Neurological assessments[7]	x	x		x	x	x	x	x	x	x			
Histological confirmation of high-grade glioma			x[4]										
Vector delivery			x										
Start Valacyclovir[6]				x Round 1				x Round 2					
Concomitant medications		x		x	x	x	x[8]	x	x[8]	x			
Adverse events				x	x	x	x[8]	x	x[8]	x			
Survival follow up											x	x	x

1. Vital signs include body weight, temperature, blood pressure, heart rate, respiration rate.
2. Hematology panel to include CBC, WBC, Differential, PT/PTT (PT/PTT only at screening).
3. Clinical Chemistry includes glucose, calcium, albumin, total protein, electrolytes [sodium, potassium CO2, chloride], BUN, creatinine, alkaline phosphatase, ALT/SGPT, AST/SGOT, bilirubin.
4. Confirmation of malignant glioma leads to formal patient enrollment, and triggers preparation of viral vectors for treatment administration. At this time, surgery informs O-CTSU that biopsy confirms histological eligibility, and treatment proceeds.
5. Post-op MRI to determine the degree of tumor resection was obtained within the first 48 hours postoperatively.
6. Valacyclovir was administered orally at 2g, 3 times daily for 14 days beginning 1-3 days after vector injection per clinician judgement. Round 2 entailed 14 days of treatment, 2g 3x/day.
7. Neurological Assessments include Mini Mental Status.
8. Survival follow-up information could be assessed by telephone calls, patient medical records, and/or clinic visits. If the patient withdrew from study, the study staff would have used a public information source (e.g., county records) when permissible, to obtain information about survival status only.

Supplementary Methods: Protocol Treatment Plan

Administration of Ad-hCMV-TK and Ad-hCMV-Flt3L

The total volume of Ad-hCMV-TK and Ad-hCMV-Flt3L injected was 2 ml.

Surgical Procedure

A craniotomy with resection of the tumor was performed. At the neurosurgeon's discretion, this involved stereotactic methods and/or intraoperative navigational guidance and/or intraoperative MRI or other radiologic guidance. After tumor resection had been completed and adequate hemostasis obtained, two tuberculin syringes were used to deliver the Ad-hCMV-TK and Ad-hCMV- Flt3L vector in 100 microliters at each of twenty sites. The assignment of dosages was determined preoperatively as per protocol (Table S1). Injections were done over 3-5 minutes for each syringe and each vector was delivered at random sites throughout the cavity. The vectors were brought from University of Michigan Research Pharmacy in sterile syringes as prepared under the supervision of a Research Pharmacist. Syringes containing vectors were delivered on ice to the OR. The surgeon placed a sterile 25-gauge needle on the syringe within the OR. The syringes did not remain in the OR for more than 4 hours before use. The injection sites were selected by the surgeon to avoid injections into adjacent motor or speech cortex, the cerebral ventricle, or seepage into the subarachnoid space. A total of 2ml of vectors will be injected as 0.1 ml/injection site across 20 sites. No injections were made into mapping-defined areas of eloquent brain to avoid any risk of injection-related complications in these areas. In addition, surgeons maintained a safety margin, such that injections of vectors were made at least one gyrus away from regions of eloquent brain. After the injections were complete, the needle was slowly withdrawn, and the remainder of the operation consisted of routine wound closure. The delivery of the viral vectors required an additional 10 minutes to the time of surgery.

Valacyclovir Administration

Valacyclovir treatment began 1-3 days after vector administration, at a dose of 2 grams given orally three times per day for a course of 14 days. A second course of valacyclovir was given beginning week 10 (+/1-2 weeks). Valacyclovir was dispensed from the University of Michigan Research Pharmacy with a medication diary, which was turned in by the patient to the study team at the end of each course of Valacyclovir.

The capacity of Ad-hCMV-TK to kill glioma cells depends on three factors that need to be present simultaneously:

• the glioma cells need to express HSV1-TK;

• the nucleoside analogue valacyclovir needs to be present; and

• the cell must enter cell division (mitosis).

The second cycle of valacyclovir is designed to target and kill residual tumor cells infected with Ad-hCMV-TK that were not dividing during the first cycle. As the population of cells that are expressing TK that do not divide early is likely to be significant (based on patterns of glioma recurrence), the second cycle of valacyclovir may be able to kill these cells, and thus increase the potential to present antigens and toll receptor ligands to immune cells recruited to the tumor microenvironment by Ad-hCMV-Flt3L. The dose/schedule of Ad-hCMV-TK has been used in clinical trials for prostate, ovarian, and malignant glioblastoma. The dose of Ad-hCMV-Flt3L was determined in this clinical trial.

Radiation Therapy (standard of care)

RT was determined and administered as per standard-of-care for the individual patient by the treating radiation oncologist. For most patients, RT began 15-35 days after Ad-hCMV-TK and Ad-hCMVFlt3L injection. It consisted of standard external field radiation, limited to the area of the tumor and brain adjacent to the tumor. The most common regimen was 60 Gy, delivered as 2 Gy per day, five days/week for six weeks. Another standard regimen was 40.05 Gy, delivered as 2.67 Gy per day, five days/week for three weeks. Neither the performance of radiation, the timing, nor the details was directed by this protocol.

Temozolomide Therapy (standard of care)

Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Treatment with temozolomide was determined as per standard-of-care for the individual patient by the treating neuro-oncologist. It was anticipated that, for most patients, concomitant temozolomide would be taken with RT starting 15-35 days after Ad-hCMV-TK and Ad-hCMVFlt3L injection. It was also anticipated that, for most patients, the duration of concomitant temozolomide would coincide with the duration of RT, as described above. It was also anticipated that neither the performance of radiation, the timing, nor the details were directed by this protocol.

***Pneumocystis carinii* (PCP, also known as *Pneumocystis jirovecii*) Prophylaxis.**

Some physicians recommend trimethoprim/sulfamethoxazole or other medications as prophylaxis for PCP for patients treated with temozolomide. There is no national standard-of care and no standard practice at the University of Michigan. The use of PCP prophylaxis was not directed by this protocol.

Maintenance Phase (Standard of Care)

Standard-of-care treatment generally includes cyclic temozolomide, starting about 4 weeks after completion of RT with concomitant temozolomide, take on five successive days every 28 days (1 cycle) for 6-12 cycles, if the tumor has not progressed. It was anticipated that most patients in this protocol would take 1-2 cycles of temozolomide during the 16-week period of intense monitoring. Decisions about cyclic temozolomide were made by the treating neuro-oncologist per standard of care. Neither the administration of cyclic temozolomide, its timing, nor its details are directed by this protocol.

Supplementary Methods: Toxicities and Dose Delays

Dose -Delays/ Potential Complications Specific to Adenoviral Vector Infusion

Fever may occur due to the local inflammatory and immune response to Ad-hCMV-TK and AdhCMV-Flt3L; acetaminophen will be used as necessary. If grade 2 or greater NCI CTCAE v.4 criteria for infection of the surgical wound is present (i.e., requiring systemic antibiotics therapy for treatment), valacyclovir was not started or stopped. If the course of valacyclovir had not yet been started, then the patient would receive the full dose. If the course of valacyclovir had been stopped, then the patient would receive the remainder. Any such dose modification was noted.

In previous clinical trials evaluating Ad-hCMV-TK followed by prodrug administration, toxicity had been rare and the overall approach had been well tolerated. In a similar study in recurrent brain tumors, CNS toxicity (lethargy, confusion, grade 3 hyponatremia, fever, leukocytosis, intratumoral hemorrhage, and hydrocephalus) was observed in the $2x10^{12}$ vp dose level. In the lower dose levels, no DLTs were observed; however transient and less severe events included seizure, small intratumoral hemorrhage, worsening of neurologic symptoms, mild hyponatremia. However, as the combination of Ad-hCMV-TK and Ad-hCMV-Flt3L in combination with surgery, radiation therapy, and chemotherapy had not yet been evaluated in human clinical trials, we chose to evaluate in the Phase 1 study dose levels of Ad-hCMV-TK that had been shown to be well tolerated over a number of studies.

Valacyclovir

The most common adverse events with valacyclovir reported in the prescribing literature are nausea in 6-15% of patients, headache in 14-35%, vomiting in 1-6%, dizziness or abdominal pain in 2-11%, arthralgia in 1-6% and depression in 1-7%. Laboratory abnormalities such as abnormal liver function tests had been observed in 1-4% of patients, while anemia, leucopenia, thrombocytopenia and elevated serum creatinine occurred in 1% of patients or less. In addition, the following adverse events have been identified in clinical practice: allergic reactions (anaphylaxis, angioedema, dyspnea, pruritus, rash and uticaria), CNS symptoms

(confusion, insomnia, hallucinations, agitation, aggressive behavior, mania), gastrointestinal (diarrhea), renal failure, erythema multiforme, facial edema, hypertension and tachycardia. A rare but serious adverse event of thrombotic thrombocytopenia purpura/hemolytic uremic syndrome (TTP/HUS), in some cases resulting in death, has been observed in clinical trials of high dose valacyclovir (8 grams per day) in patients with advanced HIV infection, and in allogeneic bone marrow transplant and renal transplant recipients.

Valacyclovir Dose Modifications (Dose Hold, Delay or Discontinuation) due to AEs

Subjects who experience a Grade 3 or greater NCI CTCAE v.4 Thrombotic thrombocytopenia purpura or Grade 2 or greater Hemolytic uremic syndrome or Grade 3 or greater serum creatinine were managed as outlined below in Tables S2 and S3. Adjustments to the dose reduction guidelines was based on the clinical judgment of the Investigator with approval by the Medical Monitor.

- For all patients starting valacyclovir, baseline creatinine within 3 d before start of treatment, were measured.
- For patients who started with a normal/baseline creatinine level, recheck at day 7 + 2 d, was performed.
- For patients who started with elevated creatinine levels, recheck at least twice a week (every 4 d) through the 14 days, was performed.

If dosing was delayed for four weeks or longer, the cycle of valacyclovir was discontinued.

For patients starting cycle 2 of valacyclovir who had creatinine elevation during cycle 1, the following criteria were used:

- If max creatinine was Grade 1, start at dose level 0 or lower at discretion of investigator; if started lower and tolerated, increase one level at discretion of investigator.
- If max creatinine was Grade 2, start at dose level 1 or lower at discretion of investigator; if tolerated, increase one level at discretion of investigator.

Temozolomide

Temozolomide is a standard-of-care treatment for glioblastoma. Its use was not mandated or directed by the protocol, but it was expected that most patients would receive it. In patients receiving temozolomide, toxicities known compatible with temozolomide as the cause will not be considered as DLTs from the treatments administered as part of this study.

Patients treated with temozolomide have reportedly experienced myelosuppression including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medications associated with aplastic anemia including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim complicates assessment. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression.

Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have also been observed. Prophylaxis against *Pneumocystis carinii* pneumonia will be left to the discretion of the treating physician. There may be a higher occurrence of PCP when temozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide, particularly patients receiving steroids, should be observed closely for the development of PCP regardless of the regimen.

Grade 3/4 neutropenia occurred in 8% and Grade 3/4 thrombocytopenia in 14% of patients treated with temozolomide. The most common side effects associated with temozolomide therapy are nausea, vomiting, anorexia, alopecia, headache, fatigue, constipation, convulsions, weakness, and thrombocytopenia.

Supplementary Methods: Clinical and Imaging Evaluation

Subjects were followed closely with clinical and radiographical assessments for 30 days after the completion of the second valacyclovir course, approximately 16 weeks from the dual vector administration, and thereafter for survival. Disease progression was determined using the immunotherapy response assessment in neuro-oncology (iRANO) criteria.[1] Detailed Schedule of Assessments can be found in the Supplemental Methods Section in the Supplementary Appendix.

The relationship between pre-operative diffusion-weighted imaging (DWI) and dynamic susceptibility contrast (DSC) perfusion-weighted imaging parameters and survival were analyzed using Pearson's correlation analyses. The mean apparent diffusion coefficient (ADCmean), relative cerebral blood flow (rCBF), and relative cerebral volume (rCBV) were measured using volume-of-interest placed on the enhanced areas of the tumors. Normalized ADCmean (nADCmean), normalized rCBF (nrCBF), and normalized rCBV (nrCBV) were calculated by dividing by the reference values which were measured using three separate regions-of-interest placed in the normal-appearing white matter.

Supplementary Methods: Correlative Studies

Multiplex immunofluorescence and analysis using the Akoya PhenoCycler-Fusion.

Multiplex immunofluorescence of all FFPE tissue (Figure 4) was performed on a PhenoCycler-Fusion by Akoya Biosciences per manufacturer's instructions with the following addition. After antigen retrieval, a photobleaching protocol was performed to reduce autofluorescence. Briefly, slides were submerged in a solution of 30% w/v hydrogen peroxide, 1x PBS and 1M sodium hydroxide and sandwiched between two full spectrum LED light boxes for thirty minutes. Samples were then equilibrated in four three-minute 1x PBS washes before continuing with the remainder of the Akoya protocol. All the antibodies, except for the Anti-Hu IBA1 antibody, were obtained from Akoya Biosciences, Inc. The Anti-Hu IBA1 antibody was a custom conjugate created using an Abcam antibody (catalog number Ab221790) and was visualized with an Alexa Fluor™ 488 reporter. Further details regarding the antibodies used can be found in the supplemental appendix (Table S7). For the Akoya protocol, samples are stained with antibodies conjugated to unique oligonucleotide sequences (i.e., barcodes). Reporters, consisting of fluorophores attached to oligonucleotide sequences complementary to those on the barcodes, are hybridized and imaged three at a time in consecutive cycles on the Phenocycler-Fusion platform.

After completing the PhenoCycler-Fusion run, we imported the QPTIFF images into QuPath version 0.4.0 for sample annotation, cell segmentation, and phenotyping.[2] Initially, we annotated the whole tissue section images. We then excluded areas with artifacts and putative non-tumor tissue. Exclusion was determined based on marker expression (SOX2, GFAP, and vimentin) and cell density. After annotation, segmentation was performed on the final annotation using the StarDist segmentation script.[3] We carried out phenotyping using a hierarchical scheme implemented with a script using single intensity thresholds for each marker as shown in supplemental appendix (Figure S7A). The phenotyping was performed on approximately 4.1 million total cells from 16 samples.

Once the classification of all cells was complete, we exported the data into CytoMAP for neighborhood analysis. We defined raster scanned neighborhoods with a 50-micron radius and clustered resulting neighborhoods into regions. The Davies Bouldin criteria was used to determine the number of regions, and the NN self-organizing map algorithm was employed for clustering the neighborhoods into regions. We then analyzed region statistics to investigate changes in

neighborhood composition using cluster composition. In CytoMAP, cluster composition is defined as the average number of a particular cell type in neighborhoods within a given region. For instance, we analyzed the average number of CD8 T cells per neighborhood within a specific region.

Statistical Analysis

A generalized linear mixed effects regression model was employed to compare the rates of cell type counts between two different time points. The model assumed a negative binomial distribution, with a log link function and log (total cell) included as the offset in the regression. The results reported included the rate ratio (RR) and p-value. To control the family-wise type I error rate, the p-values were adjusted using the Sidak correction method.

Statistical analysis of immunohistochemistry

For each marker (i.e., CD8), a linear mixed effects (LME) model was used to compare NumPos (log-transformed) between two surgery procedures. Random effect was included in the LME model to consider correlations between data measured on the same subject. Significance is determined if $p<0.05$. All analyses were conducted using SAS (version 9.4, SAS Institute, Cary, NC).

Antibody measurements

Prior to viral vector injection, circulating neutralizing anti-adenovirus antibody titers were measured,[4-6] then at week 1, 2, 6, 10 and 48. The titers were expressed as follows: 1:16, is expressed as 16, etc.; the higher the number the higher the anti-adenoviral titer. The neutralizing anti-adenovirus antibody titers were measured in patients' serum samples. Sera were heat-inactivated at 56 °C for 30 min and serially diluted 2-fold in DMEM with 10% FBS 12 times (1:2- 1:4096). Each dilution was incubated with $1x10^6$ i.u. of RAd35 (Ad-hCMV-LacZ) for 90 min at 37 °C. Volumes of 50 µL of each dilution were transferred to 96-well plate containing 4 x 10^4 HEK 293 cells for 60 min at 37 °C (performed by triplicates), followed by a 50 µL addition of DMEM with 10% FBS in each well. After 20h at 37 °C cells were fixed with 4% paraformaldehyde in PBS and stained with 5-bromo-4chloro-indolyl-ß-D-galactoside (X-gal). The neutralizing anti-adenovirus antibody titers for each sample was defined as the reciprocal of the highest dilution of serum at which 50% of RAd35-mediated transduction was inhibited.

Supplementary Results: MRI Studies

An association between lower ADC (apparent diffusion coefficient) values and poor survival have been reported in glioblastoma.[7-9] A systematic review and meta-analysis data also suggest significant correlation

of pretreatment low ADC values with poor survival in patients with recurrent GBM treated with bevacizumab.[9] Given the heterogeneity of the treatment course among the patients in this study such as additional resection that modify the appearance of target lesion at the follow up imaging, the pre-operative baseline DWI and DSC parameters were analyzed. Although no significant correlations were found between MRI parameters and survival, there were weak correlations between baseline pre-operative nrCBV and OS, and between pre-operative nADC mean and OS.

Table S1. Dual Viral Vector Dosing

Cohort	Ad-hCMV-TK (10^N vp)	Ad-hCMV-Flt3L (10^N vp)
A	10	9
B	11	9
C	10	10
D	11	10
E	10	11
F	11	11

Table S2. Dose Modification for Valacyclovir

Dose level	
0 (starting)	2 g TID
-1	2 g BID or 1 g TID
-2	1 g BID or 0.5 g TID

Table S3. Renal Adverse Event Management Algorithm for Valacyclovir

Grade of Creatinine Elevation (NCI CTCAE v4.0)	Management	Follow up
Grade 0 (i.e. normal / baseline)	Check creatinine at day 7 ± 2 days	If creatinine recheck is abnormal, continue to recheck at least twice a week through the 14-day course of valacyclovir.
Grade 1 Creatinine >1 to 1.5 x baseline; >ULN to 1.5 x ULN	Dose level level -1	If creatinine remains Grade 1 or returns to Grade 0, continue level -1. If creatinine reaches to Grade 2, reduce to level -2. If creatinine reaches Grade 3-4 withhold valacyclovir.
Grade 2 Creatinine >1.5 to 3 x baseline; >1.5 to 3 x ULN	Dose level level -2	If creatinine returns to baseline, continue dose level -1. If creatinine reaches to Grade 2, reduce to level -2. If creatinine reaches Grade 3-4, withhold valacyclovir.
Grade 3 Creatinine > 3 x baseline; >3 to 6 x ULN	Withhold valacyclovir	If creatinine returns to Grade 0, restart at level -1. If creatinine returns to Grade 1, restart at level -2. If creatinine reaches Grade 3 a second time during cycle of valacyclovir, permanently discontinue unless an associated cause was present (dehydration, concomitant medication) and can be avoided. In such a situation, restart at level -2 and increase to level -1 at discretion of investigator.
Grade 4 Creatinine >6 x ULN	Withhold valacyclovir	If creatinine returns to Grade 0, restart at level -1. If creatinine returns to Grade 1, restart at level -2.

Table S4. Patient Demographics and Baseline Characteristics

ID	Sex/ Age Range	KPS	Dual vector dose level	Extent of Surgery #1*	Diagnosis	MGMT promotor methylated	Steroids before surgery #1*	Subsequent surgery: Months from #1 / PD$^{\%tumor\ if\ \leq 50\%}$ vs PsP$^{\%tumor}$			OS (months)
								#2	#3	#4	
1	F/61-70	90	A	Near GTR	GBM	No	N	14.5/PD$^{20\%}$	24.0/PD$^{30\%}$		27.5
2	F/61-70	80	A	GTR	Anaplastic ependymoma	No	Y	13.0/PD	24.9/PD	26.7/PD	52.7
3	F/61-70	90	A	GTR	GBM	Yes	Y	17.0/PD			24.3
4	M/71-80	90	B**	Near GTR	GBM	No	Y				**
5	M/51-60	100	B	Near GTR	GBM	No	Y	19.4/PsP$^{0\%}$			26.1
6	F/61-70	70	B	Near GTR	GBM	Yes	N				5.3
7	M/61-70	100	B	Near GTR	GBM	No	Y	13.9/PsP$^{2\%}$			21.9
8	F/51-60	90	C	Near GTR	GBM	Yes	N	7.6/PD$^{45\%}$	19.0/PsP$^{5\%}$		33.3
9	Screen fail (positive pregnancy test)										
10	M/61-70	70	C	GTR	GBM	Yes	N				9.4
11	M/61-70	90	C	Near GTR	GBM	No	N				21.0
12	M/41-50	100	D	GTR	Gliosarcoma	No	Y				11.1
13	M/61-70	100	D	GTR	GBM	No	N				20.5
14	M/51-60	100	D	GTR	GBM	No	N	9.2/PD			21.6
15	M/71-80	100	E	GTR	GBM	Yes	N				8.1
16	F/61-70	90	E	GTR	GBM	Yes	Y				57.4+
17	Screen fail (frozen pathology: metastatic carcinoma)										
18	M/61-70	90	E	GTR	GBM	No	N				16.6
19	M/51-60	90	F	STR	Gliosarcoma	No	Y				7.1
20	F/71-80	100	F	GTR	Gliosarcoma	Yes	Y				15.7
21	F/61-70	100	F	GTR	GBM	No	Y	16.6/PD$^{50\%}$	28.6/PD$^{20\%}$		39.7

Abbreviations: KPS, Karnofsky Performance Status; OS, overall survival; GTR, gross total resection; GBM, glioblastoma; PD, progression of disease; PsP, pseudoprogression.

* Surgery #1 = initial surgery at the time of enrollment.
**Non-evaluable per protocol due to early withdrawal per patient discretion. Dose level subject replaced and subject 4 excluded from survival analysis. See CONSORT flow diagram.

Table S5. All Serious Adverse Events

Event	Any Grade *no. (%)*	Grade 2-3 *no. (%)*	Grade 4-5 *no. (%)*
Gastrointestinal disorders			
Nausea	1 (6)	1 (6)	-
General disorders and administration site conditions			
Pain	2 (11)	2 (11)	-
Infections and infestations			
Urinary tract infection	2 (11)	2 (11)	-
Wound infection	4 (22)	4 (22)	-
Injury, poisoning and procedural complications			
Wound dehiscence	1 (6)	1 (6)	-
Metabolism and nutrition disorders			
Dehydration	1 (6)	1 (6)	-
Nervous system disorders			
Cognitive disturbance	1 (6)	1 (6)	-
Dysphasia	2 (11)	2 (11)	-
Edema cerebral	1 (6)	-	1 (6)
Encephalopathy	1 (6)	1 (6)*	-
Intracranial hemorrhage	1 (6)	-	1 (6)
Lethargy	1 (6)	1 (6)	-
Right side neglect	1 (6)	1 (6)	-
Seizure	2 (11)	2 (11)*	-
Syncope	1 (6)	1 (6)	-
Confusion	1 (6)	1 (6)	-
Renal and urinary disorders			
Acute kidney injury	1 (6)	1 (6)*	-
Respiratory, thoracic and mediastinal disorders			
Respiratory failure	1 (6)	-	1 (6)
Vascular disorders			
Thromboembolic event	5 (28)	5 (28)	-
Total no. patients with SAE	10 (56)	9 (50)	3 (17)

*Possibly attributable to study intervention

Table S6. Adverse Events Unrelated to Study Intervention

Event	Grade 2-3 *no. (%)*	Grade 4-5 *no. (%)*
Blood and lymphatic system disorders		
Anemia	4 (22)	-
Cardiac disorders		
Pericardial effusion	1 (6)	-
Ear and labyrinth disorders		
Vestibular disorder	1 (6)	-
Gastrointestinal disorders		
Abdominal pain	3 (17)	-
Diarrhea	1 (6)	-
Dysphagia	1 (6)	-
Nausea	3 (17)	-
General disorders and administration site conditions		
Edema limbs	2 (11)	-
Fatigue	8 (44)	-
Pain	3 (17)	-
Infections and infestations		
Upper respiratory infection	2 (11)	-
Urinary tract infection	3 (17)	-
Wound infection	4 (22)	-
Injury, poisoning and procedural complications		
Wound dehiscence	1 (6)	-
Investigations		
Creatinine increased	2 (11)	-
Neutrophil count decreased	1 (6)	-
Platelet count decreased	4 (22)	-
Metabolism and nutrition disorders		
Dehydration	2 (11)	-
Hyperkalemia	1 (6)	-
Hypokalemia	1 (6)	-
Musculoskeletal and connective tissue disorders		
Arthralgia	1 (6)	-
Generalized muscle weakness	2 (11)	-
Muscle weakness lower limb	1 (6)	-
Muscle weakness right-sided	1 (6)	-
Pain in extremity	1 (6)	-

Event (cont.)	Grade 2-3 *no. (%)*	Grade 4-5 *no. (%)*
Nervous system disorders		
Cognitive disturbance	1 (6)	-
Dysarthria	2 (11)	-
Dysphasia	3 (17)	-
Edema cerebral	-	3 (17)
Facial muscle weakness	1 (6)	-
Headache	2 (11)	-
Intracranial hemorrhage	-	1 (6)
Lethargy	1 (6)	-
Paresthesia	1 (6)	-
Right side neglect	1 (6)	-
Seizure	2 (11)	-
Syncope	1 (6)	-
Visual field deficit	1 (6)	-
Psychiatric disorders		
Agitation	1 (6)	-
Confusion	1 (6)	-
Insomnia	1 (6)	-
Respiratory, thoracic and mediastinal disorders		
Hypoxia	1 (6)	-
Respiratory failure	-	1 (6)
Skin and subcutaneous disorders		
Alopecia	2 (11)	-
Thromboembolic event	7 (39)	-

Table S7. Antibodies used in Multiplex Immunohistochemistry

Antibody	Company	Catalog #	Clone	Dilution	Exposure (ms)
Anti-Hu CD3e-BX045—Alexa Fluor™ 647 for PhenoCycler	Akoya	4550119	AKYP0062	1:200	250
Anti-Hu CD4-BX003—Alexa Fluor™ 647 for PhenoCycler	Akoya	4550112	AKYP0048	1:200	200
Anti-Hu CD8a-BX026—Atto 550 for PhenoCycler	Akoya	4250017	AKYP0028	1:200	150
Anti-Hu Granzyme B-BX041—Atto 550 for PhenoCycler	Akoya	4250055	AKYP0086	1:100	150
Anti-Hu CD107a-BX006—Alexa Fluor™ 647 for PhenoCycler	Akoya	4550098	AKYP0004	1:100	150
Anti-Hu CD11c-BX024—Alexa Fluor™ 647 for PhenoCycler	Akoya	4550114	AKYP0051	1:200	150
Anti-Hu HLA-DR-BX033—Alexa Fluor™ 647 for PhenoCycler	Akoya	4550118	AKYP0063	1:200	150
Anti-Hu CD45-BX021—Alexa Fluor™ 647 for PhenoCycler	Akoya	4550121	AKYP0074	1:200	150
Anti-Hu SOX2-BX102—Atto 550 for PhenoCycler	Akoya	4250075	AKYP0106	1:200	150
Anti-Hu FOXP3-BX031—Alexa Fluor™ 647 for PhenoCycler	Akoya	4550071	AKYP0102	1:200	250
Anti-Hu IBA1-BX040—Alexa Fluor™ 488 for PhenoCycler	Abcam	Ab221790	EPR16589	1:200	150

Figure S1. Ad-hCMV-TK expresses bioactive transgene herpes simplex type 1 thymidine kinase (TK)





C

Expected (EcoRV)	Actual (EcoRV)	Expected (HindIII)	Actual (HindIII)
7637	7637	8009	8009
6965	6935	5553	5553
6355	6355	5322	5322
4545	4545	4597	4597
2617	2617	2937	2937
2182	2182	2927	2927
2052	2052	2081	2081
1238	1238	1824	1824
1106	1106	1008	1008
104		468	
		75	

Supplemental Figure S1. Ad-hCMV-TK expresses bioactive transgene herpes simplex type 1 thymidine kinase (TK). A) CNS1 rat glioma cells (2 x 104/well) were infected with Ad-hCMV-TK with 10,000, 1,000, 100, 10, 0 Ad-hCMV-TK/cell. After 24 hours, the cells were incubated for additional 72 hours in the presence of 1 mg/mL of the prodrug ganciclovir (GCV). Cell viability was determined by CTG assay (Cell Titer-Glo Cell Viability Assays, Promega, Madison, WI). **B)** Restriction Analysis of Ad-hCMV-TK. Viral DNA was isolated from Ad-hCMV-TK, digested with either HindIII or EcoRV, and run on a 0.8% agarose gel. Image of gel electrophoresis displays a gel after 90 min of electrophoresis. **C)** Table comparing the predicted and actual DNA size following restriction analysis. All sizes are described in base pairs (bp).

Figure S2. Ad-hCMV-Flt3L expresses its transgene human soluble FMS-like tyrosine kinase 3 ligand



C

Expected (EcoRV)	Actual (EcoRV)	Expected (HindIII)	Actual (HindIII)
8139	8139	8009	8009
7637	7637	5553	5553
6355	6355	5322	5322
4545	4545	4597	4597
2617	2617	2997	2997
2182	2182	2927	2927
2052	2052	2081	2081
1238	1238	1432	1432
		1008	
		468	
		410	
		75	

Supplemental Figure S2. Ad-hCMV-Flt3L expresses its transgene human soluble FMS-like tyrosine kinase 3 ligand. A) CNS1 rat glioma cells (2 x 104/well) were infected with Ad-hCMV-Fl3tL with 10,000, 1,000, 100, 10, 0 Ad-hCMV-Fl3tL /cell. After 72 hours, the levels of hFlt3L were measured in the cell supernatants using Flt3L specific ELISA. **B)** Restriction Analysis of Ad-hCMV-TK. Viral DNA was isolated from Ad-hCMV-Flt3L, digested with either HindIII or EcoRV, and run on a 0.8% agarose gel. Image of gel electrophoresis displays a gel after 90 min of electrophoresis. **C)** Table comparing the predicted and actual DNA size following restriction analysis. All sizes are described in base pairs (bp).

Figure S3. The CONSORT flow diagram



Supplemental Figure S3. The consort flow diagram. Flow diagram of the enrollment, intervention allocation, follow-up, and data analysis of the dose-finding trial of combined cytotoxic and immune-stimulatory and adenovirally mediated strategy using FLT3L and HSV1-TK.

Figure S4. Immunohistochemical analysis of CD45+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence



Supplemental Figure S4. Immunohistochemical analysis of CD45+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A and C) Representative images of CD45 expression. Scale bar: 20µm. **B)** Box plots and lines graphs represent the quantification of CD45+ cells numbers (cells/mm2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-TK-FLt3 treatment (Surgery 2). Error bars represent ±SEM. n=8 patients, ns = non-significant.

Figure S5. Immunohistochemical analysis of CD68+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence



Supplemental Figure S5. Immunohistochemical analysis of CD68+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A and C) Representative images of CD68 expression. Scale bar: 20µm. **B)** Box plots and lines graphs represent the quantification of CD68+ cells numbers (cells/mm2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-TK-FLt3 treatment (Surgery 2). Error bars represent ±SEM. n=8 patients, ns = non-significant.

Figure S6. Immunohistochemical analysis of CD4+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence



Supplemental Figure S6. Immunohistochemical analysis of CD4+ cells in human glioblastoma tissue at primary resection (surgery 1), pre vector TK-Flt3L treatment, and at secondary surgery due to tumor recurrence. A and C) Representative images of CD4 expression. Scale bar: 20µm. **B)** Box plots and lines graphs represent the quantification of CD4+ cells numbers (cells/mm2) using QuPath positive cell detection on glioblastomas samples obtained pre-TK-Flt3 treatment (Surgery 1) and post-TK-FLt3 treatment (Surgery 2). Error bars represent ±SEM. n=8 patients, ns = non-significant.

Figure S7

A



B



C



D



E



F



G



H



Figure S7: Phenotyping and quantification of immune cell types in the biopsies obtained at primary tumor resection and post dual-vector TK-Flt3L treatment at tumor recurrence. Cell classification was performed using a decision tree shown with single intensity thresholds for each marker, coded into a script used in QuPath **(A)**. Spaghetti plots were generated to represent the percentage of CD4+ T cells out of total cells **(B)**, cytotoxic CD4+ T cells out of total cells **(C)**, cDCs/monocytes out of total cells **(D)**, double negative T cells out of total cells **(E)**, macrophages out of total cells **(F)**, Tregs out of total cells **(G)**, and other leukocytes out of total cells **(H)** in surgery 1 and surgery 2 samples.

Figure S8


A
CD45
HLA-DR
Merge
20 µm
B
CD45
CD3e
Merge
CD8
CD4
20 µm
C
CD45
CD3e
Merge
CD8
GzB
20 µm

Figure S8: Multiplex immunocytochemical analysis of immune cells in the biopsies obtained post-dual vector TK-Flt3L treatment at tumor recurrence. Panel A) shows representative images of colocalization of CD45 and HLA-DR expression, which were used to identify pDCs. In panel B), representative images of colocalizing CD45, CD3e, CD8, and CD4 expression were presented, which were used to identify double positive T cells. Panel C) displays representative images of colocalizing CD45, CD3e, CD8, and granzyme B expression, which were used to identify both cytotoxic CD8+ T cells and CD8+ T cells.

Figure S9


A
Patient 1
Surgery 1
Patient 1
Surgery 2
Immune Region
Tumor Region
Other Region
y (µm)
x (µm)
% of tissue
S1
S2
B
Patient 2
Surgery 1
Patient 2
Surgery 2
C
Patient 3
Surgery 1
Patient 3
Surgery 2
D
Patient 5
Surgery 1
Patient 5
Surgery 2
Y (µm)
X (µm)

Figure S9: Neighborhood analysis of the tumor microenvironment in the biopsies obtained at primary tumor resection and at tumor recurrence. The plots illustrate the cells present in the resected tissue of both primary (on the left) and recurrent (in the middle) tumors, with each cell colored according to its corresponding region type for the specified patient. The accompanying bar graph on the right displays the prevalence of each region type in the tissue samples. The four different patients are labelled as follows: **A)** patient 1, **B)** patient 2, **C)** patient 3, and **D)** patient 5.

Figure S10



Figure S10: Neighborhood analysis of the tumor microenvironment in glioblastoma tissues at primary tumor resection and at tumor recurrence. The figures depict the cellular composition of resected tissue from primary (on the left) and recurrent (in the middle) tumors, with each cell colored based on its corresponding region type for the indicated patient. The corresponding bar graph on the right illustrates the relative frequency of each region type detected in the tissue specimens. The three patients are labelled as follows: **A)** patient 7, **B)** patient 8, and **C)** patient 14.

Figure S11



Figure S11. Comparison of average cell-cell correlations across six patients exhibiting immune infiltration at tumor recurrence. A) Average cell-cell correlations for patients 1, 5, 7, 8, 14 & 21 at primary tumor resection. Interactions between T cells and macrophages denoted with green box, while strong cell-cell association between macrophages and tumor cells denoted with pink box (indicated by black arrows). **B)** Average cell-cell correlations for the same six patients at surgery 2. The green box denotes interactions between T cells and macrophages, and the higher cell-cell associations between many T cells and macrophages at surgery 2 indicate increased interactions between these immune cell types. Decreased cell-cell correlation between macrophages and tumor cells compared to surgery 1 is denoted with a pink box. **C) and D)** Heat map of p-values corresponding to correlations in panel A and B, respectively.

Figure S12

A **Patient #2 (Ad-TK 10^{10} vp): 395 days after treatment**

HSV1-TK DAPI



Patient #7(Ad-TK 10^{11} vp) 425 days after treatment

HSV1-TK DAPI



Patient #8 (Ad-TK 10^{10} vp) 233 days after treatment

HSV1-TK DAPI



Patient #14 (Ad-TK 10^{11} vp) 281 days after treatment

HSV1-TK DAPI



Patient #21 (Ad-TK 10^{11} vp) 506 days after treatment

HSV1-TK DAPI



Figure S12: Persistent expression of HSV1-TK post dual-vector TK-Flt3L treatment at tumor recurrence. To assess the long-term expression of HSV1-TK (red), we utilized sections of recurrent tumor biopsies obtained at second surgery. **A)** The representative sections of patients who tested positive for HSV1-TK are displayed, along with information about the viral dosage received and the number of days that elapsed after treatment administration. The nuclei were counterstained with DAPI (blue). We could detect HSV1-TK in 5 out of 8 samples from surgery 2, up to 17 months post-viral administration.

Figure S13



Figure S13: Neutralization experiments to validate the specificity of HSV1-TK detection. A) The consecutive sections of surgery 2 (recurrent tumor) from patient #21 were used in the same location to demonstrate the specificity of the HSV1-TK antibody. The antibody was pre-incubated with cells infected with either Ad-βGal or Ad-TK. Pre-absorption with an unspecific protein (βGal) did not interfere with the positive cells, whereas pre-absorption with HSV1-TK neutralized the antibody, thereby demonstrating the specificity of this detection. Hematoxylin and eosin staining of the same area was imaged to provide a general overview of the tissue at that location. Each square denotes the inset displayed in the image below, with the highest magnification displayed in the main manuscript Figure 5B.

Figure S14

A

Cohort	Patient	Initial screening	Week 2
A	1	ND	ND
	2	ND	ND
	3	ND	ND
B	5	64	>4096
	6	ND	1024
	7	2048	>4096
C	8	32	64
	10	32	64
	11	2	16
D	12	8	>4096
	13	512	>4096
	14	<2	512
E	15	ND	>4096
	16	<2	16
	18	<2	>4096
F	19	ND	512
	20	<2	128
	21	ND	>4096

ND = not determined

B



Figure S14: Detection of anti-adenovirus antibodies in plasma following dual vector treatment. A) Cohort B-F patients' plasma samples were collected during initial screening (before surgery) and again 2 weeks after surgery/treatment. These samples were then tested for anti-adenovirus antibodies using a neutralization assay, with the titer indicating the level of antibodies present - the higher the number, the stronger the anti-adenoviral response. **B)** The results were plotted to show the anti-adenovirus antibody titer (log2) at the initial screening and 2 weeks after treatment administration. The statistical analysis revealed a significant difference, with a p-value of 0.0005.

Supplemental References

1. Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16(15):e534-e542. DOI: 10.1016/S1470-2045(15)00088-1.
2. Bankhead P, Loughrey MB, Fernandez JA, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep 2017;7(1):16878. DOI: 10.1038/s41598-017-17204-5.
3. Schmidt U, Weigert M, Broaddus C, Myers G. Cell Detection with Star-Convex Polygons. In: Frangi AF, Schnabel JA, Davatzikos C, Alberola-López C, Fichtinger G, eds. Medical Image Computing and Computer Assisted Intervention – MICCAI 2018. Cham: Springer International Publishing; 2018:265-273.
4. Muhammad AK, Xiong W, Puntel M, et al. Safety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trial. Hum Gene Ther Methods 2012;23(4):271-84. DOI: 10.1089/hgtb.2012.060.
5. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 2000;97(13):7482-7. DOI: 10.1073/pnas.120474397.
6. Puntel M, Kroeger KM, Sanderson NS, Thomas CE, Castro MG, Lowenstein PR. Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci 2010;Chapter 4:Unit 4 24. DOI: 10.1002/0471142301.ns0424s50.
7. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108(3):491-8. DOI: 10.1007/s11060-012-0847-y.
8. Schell M, Pfluger I, Brugnara G, et al. Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro Oncol 2020;22(11):1667-1676. DOI: 10.1093/neuonc/noaa120.
9. Kurokawa R, Baba A, Kurokawa M, et al. Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis. AJNR Am J Neuroradiol 2022;43(2):202-206. DOI: 10.3174/ajnr.A7406.